Table 2: Updated MIPS Benchmark Results Using DY2016 and PY2018 Logic,,,,,,,,,,,,,
,,,,,,,,,,,,,
Measure_Name,Measure_ID,Submission_Method,Measure_Type,Benchmark,Decile_3,Decile_4,Decile_5,Decile_6,Decile_7,Decile_8,Decile_9,Decile_10,TOPPED_OUT
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,CMS Web Interface,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,Claims,Intermediate Outcome,Y,48.98 - 34.30,34.29 - 21.44,21.43 - 15.60,15.59 - 11.44,11.43 - 8.58,8.57 - 5.67,5.66 - 2.87,<= 2.86,No
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,EHR,Intermediate Outcome,Y,77.27 - 61.44,61.43 - 49.22,49.21 - 39.30,39.29 - 31.97,31.96 - 26.01,26.00 - 20.63,20.62 - 14.75,<= 14.74,No
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,Registry/QCDR,Intermediate Outcome,Y,68.42 - 51.70,51.69 - 38.34,38.33 - 29.09,29.08 - 20.01,20.00 - 13.47,13.46 - 9.10,9.09 - 3.22,<= 3.21,No
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,EHR,Process,Y,74.19 - 78.89,78.90 - 82.21,82.22 - 85.23,85.24 - 87.92,87.93 - 90.73,90.74 - 93.51,93.52 - 97.72,>= 97.73,No
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,Registry/QCDR,Process,Y,93.33 - 96.96,96.97 - 98.40,98.41 - 99.99,--,--,--,--,100.00,Yes
Coronary Artery Disease (CAD): Antiplatelet Therapy,6,Registry/QCDR,Process,Y,83.94 - 87.79,87.80 - 90.54,90.55 - 92.73,92.74 - 94.99,95.00 - 96.90,96.91 - 99.99,--,100.00,No
Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%),7,EHR,Process,Y,76.83 - 80.66,80.67 - 83.32,83.33 - 85.40,85.41 - 87.31,87.32 - 89.86,89.87 - 91.99,92.00 - 94.99,>= 95.00,No
Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%),7,Registry/QCDR,Process,Y,95.54 - 97.82,97.83 - 99.24,99.25 - 99.99,--,--,--,--,100.00,Yes
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,EHR,Process,Y,81.25 - 86.32,86.33 - 89.39,89.40 - 91.29,91.30 - 93.28,93.29 - 94.98,94.99 - 96.42,96.43 - 99.99,100.00,No
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,Registry/QCDR,Process,Y,95.45 - 97.87,97.88 - 99.30,99.31 - 99.99,--,--,--,--,100.00,Yes
Anti-Depressant Medication Management,9,EHR,Process,Y,15.91 - 30.73,30.74 - 42.49,42.50 - 54.81,54.82 - 72.57,72.58 - 82.94,82.95 - 88.75,88.76 - 94.43,>= 94.44,No
Anti-Depressant Medication Management,9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,EHR,Process,Y,79.63 - 86.66,86.67 - 90.66,90.67 - 93.88,93.89 - 96.37,96.38 - 98.06,98.07 - 99.14,99.15 - 99.99,100.00,No
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,Registry/QCDR,Process,Y,96.51 - 99.16,99.17 - 99.99,--,--,--,--,--,100.00,Yes
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,14,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,14,Registry/QCDR,Process,Y,76.54 - 90.21,90.22 - 96.53,96.54 - 99.77,99.78 - 99.99,--,--,--,100.00,Yes
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,EHR,Process,Y,34.53 - 47.92,47.93 - 58.10,58.11 - 67.09,67.10 - 75.60,75.61 - 82.73,82.74 - 90.08,90.09 - 96.13,>= 96.14,No
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,Registry/QCDR,Process,Y,70.49 - 83.99,84.00 - 92.12,92.13 - 98.40,98.41 - 99.99,--,--,--,100.00,Yes
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin,21,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin,21,Registry/QCDR,Process,Y,98.59 - 99.99,--,--,--,--,--,--,100.00,Yes
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),23,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),23,Registry/QCDR,Process,Y,98.78 - 99.99,--,--,--,--,--,--,100.00,Yes
Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older,24,Claims,Process,Y,32.35 - 69.43,69.44 - 90.90,90.91 - 95.82,95.83 - 97.86,97.87 - 99.99,--,--,100.00,Yes
Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older,24,Registry/QCDR,Process,Y,25.58 - 46.66,46.67 - 55.31,55.32 - 62.78,62.79 - 76.89,76.90 - 88.23,88.24 - 99.99,--,100.00,No
Screening for Osteoporosis for Women Aged 65-85 Years of Age,39,Claims,Process,Y,29.84 - 39.65,39.66 - 46.80,46.81 - 53.00,53.01 - 59.13,59.14 - 66.53,66.54 - 77.77,77.78 - 91.85,>= 91.86,No
Screening for Osteoporosis for Women Aged 65-85 Years of Age,39,Registry/QCDR,Process,Y,9.87 - 20.36,20.37 - 32.24,32.25 - 43.24,43.25 - 55.55,55.56 - 66.50,66.51 - 78.78,78.79 - 88.59,>= 88.60,No
Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery,44,Registry/QCDR,Process,Y,93.33 - 96.14,96.15 - 97.43,97.44 - 99.83,99.84 - 99.99,--,--,--,100.00,Yes
Medication Reconciliation Post-Discharge,46,CMS Web Interface,Process,N,--,--,--,--,--,--,--,--,--
Medication Reconciliation Post-Discharge,46,Claims,Process,Y,95.65 - 98.32,98.33 - 99.99,--,--,--,--,--,100.00,Yes
Medication Reconciliation Post-Discharge,46,Registry/QCDR,Process,Y,94.64 - 97.96,97.97 - 99.96,99.97 - 99.99,--,--,--,--,100.00,Yes
Care Plan,47,Claims,Process,Y,47.83 - 80.21,80.22 - 92.08,92.09 - 97.02,97.03 - 99.06,99.07 - 99.99,--,--,100.00,Yes
Care Plan,47,Registry/QCDR,Process,Y,22.35 - 43.19,43.20 - 64.26,64.27 - 80.70,80.71 - 91.32,91.33 - 97.03,97.04 - 99.66,99.67 - 99.99,100.00,No
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,48,Claims,Process,Y,4.00 - 15.78,15.79 - 68.67,68.68 - 96.39,96.40 - 99.99,--,--,--,100.00,Yes
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,48,Registry/QCDR,Process,Y,10.31 - 26.56,26.57 - 47.34,47.35 - 66.41,66.42 - 82.23,82.24 - 95.10,95.11 - 99.50,99.51 - 99.99,100.00,No
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,50,Claims,Process,Y,91.60 - 97.55,97.56 - 99.99,--,--,--,--,--,100.00,Yes
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,50,Registry/QCDR,Process,Y,47.80 - 58.32,58.33 - 66.66,66.67 - 74.99,75.00 - 83.32,83.33 - 90.90,90.91 - 98.00,98.01 - 99.99,100.00,No
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation,51,Claims,Process,Y,27.89 - 60.26,60.27 - 88.68,88.69 - 97.68,97.69 - 99.99,--,--,--,100.00,Yes
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation,51,Registry/QCDR,Process,Y,22.89 - 40.93,40.94 - 59.93,59.94 - 74.29,74.30 - 85.49,85.50 - 93.43,93.44 - 98.75,98.76 - 99.99,100.00,No
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy,52,Claims,Process,Y,95.83 - 98.45,98.46 - 99.99,--,--,--,--,--,100.00,Yes
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy,52,Registry/QCDR,Process,Y,89.70 - 95.31,95.32 - 96.51,96.52 - 98.94,98.95 - 99.99,--,--,--,100.00,Yes
Appropriate Treatment for Children with Upper Respiratory Infection (URI),65,EHR,Process,Y,81.49 - 88.55,88.56 - 91.94,91.95 - 93.88,93.89 - 95.64,95.65 - 96.87,96.88 - 98.28,98.29 - 99.99,100.00,No
Appropriate Treatment for Children with Upper Respiratory Infection (URI),65,Registry/QCDR,Process,Y,93.29 - 96.42,96.43 - 97.32,97.33 - 98.17,98.18 - 99.01,99.02 - 99.48,99.49 - 99.99,--,100.00,Yes
Appropriate Testing for Children with Pharyngitis,66,EHR,Process,Y,36.71 - 60.31,60.32 - 72.48,72.49 - 79.05,79.06 - 83.79,83.80 - 87.37,87.38 - 91.39,91.40 - 94.58,>= 94.59,No
Appropriate Testing for Children with Pharyngitis,66,Registry/QCDR,Process,Y,63.87 - 69.43,69.44 - 74.80,74.81 - 81.51,81.52 - 84.94,84.95 - 87.94,87.95 - 91.61,91.62 - 97.54,>= 97.55,No
Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow,67,Registry/QCDR,Process,Y,8.00 - 12.49,12.50 - 22.72,22.73 - 28.52,28.53 - 34.61,34.62 - 78.78,78.79 - 99.99,--,100.00,No
Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy,68,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hematology: Multiple Myeloma: Treatment with Bisphosphonates,69,Registry/QCDR,Process,Y,42.86 - 47.49,47.50 - 64.99,65.00 - 68.11,68.12 - 71.42,71.43 - 72.72,72.73 - 76.91,76.92 - 92.30,>= 92.31,No
Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry,70,Registry/QCDR,Process,Y,16.67 - 23.20,23.21 - 32.25,32.26 - 46.56,46.57 - 67.85,67.86 - 95.44,95.45 - 99.99,--,100.00,No
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections,76,Claims,Process,Y,95.00 - 98.81,98.82 - 99.99,--,--,--,--,--,100.00,Yes
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections,76,Registry/QCDR,Process,Y,95.81 - 99.27,99.28 - 99.99,--,--,--,--,--,100.00,Yes
Acute Otitis Externa (AOE): Topical Therapy,91,Claims,Process,Y,43.88 - 87.49,87.50 - 94.78,94.79 - 99.99,--,--,--,--,100.00,Yes
Acute Otitis Externa (AOE): Topical Therapy,91,Registry/QCDR,Process,Y,65.85 - 78.56,78.57 - 85.70,85.71 - 90.90,90.91 - 94.91,94.92 - 97.05,97.06 - 99.99,--,100.00,No
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,93,Claims,Process,Y,90.58 - 93.54,93.55 - 96.35,96.36 - 97.86,97.87 - 99.92,99.93 - 99.99,--,--,100.00,Yes
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,93,Registry/QCDR,Process,Y,63.16 - 77.94,77.95 - 84.19,84.20 - 89.99,90.00 - 93.32,93.33 - 96.14,96.15 - 99.99,--,100.00,No
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients,102,EHR,Process,Y,75.02 - 81.57,81.58 - 86.27,86.28 - 94.42,94.43 - 99.37,99.38 - 99.99,--,--,100.00,No
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients,102,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer,104,Registry/QCDR,Process,Y,37.38 - 48.16,48.17 - 54.66,54.67 - 73.24,73.25 - 89.73,89.74 - 97.21,97.22 - 99.99,--,100.00,No
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment,107,EHR,Process,Y,1.27 - 3.49,3.50 - 7.81,7.82 - 17.18,17.19 - 29.69,29.70 - 53.69,53.70 - 76.98,76.99 - 94.54,>= 94.55,No
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment,107,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Osteoarthritis (OA): Function and Pain Assessment,109,Claims,Process,Y,89.71 - 96.74,96.75 - 98.99,99.00 - 99.99,--,--,--,--,100.00,Yes
Osteoarthritis (OA): Function and Pain Assessment,109,Registry/QCDR,Process,Y,30.57 - 60.80,60.81 - 84.37,84.38 - 93.37,93.38 - 99.47,99.48 - 99.99,--,--,100.00,No
Preventive Care and Screening: Influenza Immunization,110,CMS Web Interface,Process,N,--,--,--,--,--,--,--,--,--
Preventive Care and Screening: Influenza Immunization,110,Claims,Process,Y,23.31 - 34.83,34.84 - 48.47,48.48 - 65.52,65.53 - 78.71,78.72 - 91.26,91.27 - 99.02,99.03 - 99.99,100.00,No
Preventive Care and Screening: Influenza Immunization,110,EHR,Process,Y,15.36 - 23.80,23.81 - 31.46,31.47 - 38.86,38.87 - 46.90,46.91 - 56.08,56.09 - 67.58,67.59 - 84.98,>= 84.99,No
Preventive Care and Screening: Influenza Immunization,110,Registry/QCDR,Process,Y,28.11 - 40.27,40.28 - 52.67,52.68 - 64.97,64.98 - 75.39,75.40 - 86.68,86.69 - 95.68,95.69 - 99.99,100.00,No
Pneumococcal Vaccination Status for Older Adults,111,CMS Web Interface,Process,N,--,--,--,--,--,--,--,--,--
Pneumococcal Vaccination Status for Older Adults,111,Claims,Process,Y,47.63 - 58.65,58.66 - 67.61,67.62 - 75.22,75.23 - 81.17,81.18 - 87.59,87.60 - 94.53,94.54 - 99.99,100.00,No
Pneumococcal Vaccination Status for Older Adults,111,EHR,Process,Y,18.64 - 30.34,30.35 - 42.06,42.07 - 52.70,52.71 - 62.06,62.07 - 71.16,71.17 - 80.10,80.11 - 90.28,>= 90.29,No
Pneumococcal Vaccination Status for Older Adults,111,Registry/QCDR,Process,Y,29.46 - 43.80,43.81 - 54.84,54.85 - 63.25,63.26 - 69.99,70.00 - 75.83,75.84 - 83.28,83.29 - 95.00,>= 95.01,No
Breast Cancer Screening,112,CMS Web Interface,Process,N,--,--,--,--,--,--,--,--,--
Breast Cancer Screening,112,Claims,Process,Y,35.94 - 47.16,47.17 - 54.91,54.92 - 61.26,61.27 - 68.23,68.24 - 77.21,77.22 - 89.08,89.09 - 99.99,100.00,No
Breast Cancer Screening,112,EHR,Process,Y,21.98 - 32.46,32.47 - 41.82,41.83 - 50.40,50.41 - 57.79,57.80 - 65.43,65.44 - 73.21,73.22 - 82.18,>= 82.19,No
Breast Cancer Screening,112,Registry/QCDR,Process,Y,36.43 - 48.08,48.09 - 57.28,57.29 - 67.01,67.02 - 75.55,75.56 - 85.41,85.42 - 93.84,93.85 - 99.99,100.00,No
Colorectal Cancer Screening,113,CMS Web Interface,Process,N,--,--,--,--,--,--,--,--,--
Colorectal Cancer Screening,113,Claims,Process,Y,33.06 - 46.62,46.63 - 58.63,58.64 - 68.03,68.04 - 76.56,76.57 - 86.70,86.71 - 96.63,96.64 - 99.99,100.00,No
Colorectal Cancer Screening,113,EHR,Process,Y,12.58 - 23.29,23.30 - 33.02,33.03 - 43.09,43.10 - 53.50,53.51 - 63.14,63.15 - 72.66,72.67 - 82.80,>= 82.81,No
Colorectal Cancer Screening,113,Registry/QCDR,Process,Y,34.18 - 49.12,49.13 - 60.94,60.95 - 71.05,71.06 - 81.27,81.28 - 90.40,90.41 - 96.96,96.97 - 99.99,100.00,No
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis,116,Registry/QCDR,Process,Y,45.14 - 58.06,58.07 - 72.65,72.66 - 84.42,84.43 - 91.59,91.60 - 95.95,95.96 - 97.66,97.67 - 99.99,100.00,No
Diabetes: Eye Exam,117,CMS Web Interface,Process,N,--,--,--,--,--,--,--,--,--
Diabetes: Eye Exam,117,Claims,Process,Y,77.05 - 97.82,97.83 - 99.99,--,--,--,--,--,100.00,Yes
Diabetes: Eye Exam,117,EHR,Process,Y,19.82 - 31.10,31.11 - 44.00,44.01 - 62.54,62.55 - 87.03,87.04 - 95.37,95.38 - 98.19,98.20 - 99.74,>= 99.75,No
Diabetes: Eye Exam,117,Registry/QCDR,Process,Y,79.17 - 89.99,90.00 - 95.81,95.82 - 98.48,98.49 - 99.99,--,--,--,100.00,Yes
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%),118,Registry/QCDR,Process,Y,75.00 - 77.99,78.00 - 80.76,80.77 - 83.41,83.42 - 86.04,86.05 - 88.36,88.37 - 91.75,91.76 - 98.13,>= 98.14,No
Diabetes: Medical Attention for Nephropathy,119,EHR,Process,Y,67.77 - 74.77,74.78 - 79.99,80.00 - 84.10,84.11 - 87.71,87.72 - 91.09,91.10 - 94.58,94.59 - 98.46,>= 98.47,No
Diabetes: Medical Attention for Nephropathy,119,Registry/QCDR,Process,Y,73.96 - 82.87,82.88 - 87.67,87.68 - 92.07,92.08 - 97.65,97.66 - 99.99,--,--,100.00,No
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation",126,Registry/QCDR,Process,Y,66.00 - 84.71,84.72 - 96.26,96.27 - 99.99,--,--,--,--,100.00,Yes
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear",127,Registry/QCDR,Process,Y,68.91 - 90.71,90.72 - 99.21,99.22 - 99.99,--,--,--,--,100.00,Yes
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,CMS Web Interface,Process,N,--,--,--,--,--,--,--,--,--
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Claims,Process,Y,38.71 - 52.99,53.00 - 77.59,77.60 - 93.97,93.98 - 99.07,99.08 - 99.99,--,--,100.00,No
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,EHR,Process,Y,21.17 - 24.48,24.49 - 28.32,28.33 - 33.72,33.73 - 42.85,42.86 - 58.67,58.68 - 77.58,77.59 - 92.96,>= 92.97,No
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Registry/QCDR,Process,Y,32.58 - 53.68,53.69 - 73.74,73.75 - 90.38,90.39 - 97.30,97.31 - 99.82,99.83 - 99.99,--,100.00,No
Documentation of Current Medications in the Medical Record,130,Claims,Process,Y,97.74 - 99.43,99.44 - 99.90,99.91 - 99.99,--,--,--,--,100.00,Yes
Documentation of Current Medications in the Medical Record,130,EHR,Process,Y,87.52 - 93.50,93.51 - 96.34,96.35 - 98.01,98.02 - 99.02,99.03 - 99.58,99.59 - 99.88,99.89 - 99.99,100.00,Yes
Documentation of Current Medications in the Medical Record,130,Registry/QCDR,Process,Y,66.36 - 89.39,89.40 - 96.71,96.72 - 99.37,99.38 - 99.99,--,--,--,100.00,Yes
Pain Assessment and Follow-Up,131,Claims,Process,Y,87.46 - 98.21,98.22 - 99.80,99.81 - 99.99,--,--,--,--,100.00,Yes
Pain Assessment and Follow-Up,131,Registry/QCDR,Process,Y,14.86 - 36.97,36.98 - 60.63,60.64 - 81.82,81.83 - 94.09,94.10 - 99.27,99.28 - 99.99,--,100.00,No
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan,134,CMS Web Interface,Process,N,--,--,--,--,--,--,--,--,--
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan,134,Claims,Process,Y,13.70 - 57.46,57.47 - 82.57,82.58 - 98.18,98.19 - 99.99,--,--,--,100.00,Yes
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan,134,EHR,Process,Y,4.85 - 10.06,10.07 - 17.60,17.61 - 28.28,28.29 - 42.08,42.09 - 56.62,56.63 - 73.30,73.31 - 87.60,>= 87.61,No
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan,134,Registry/QCDR,Process,Y,14.36 - 40.55,40.56 - 70.28,70.29 - 85.70,85.71 - 98.27,98.28 - 99.99,--,--,100.00,No
Melanoma: Continuity of Care - Recall System,137,Registry/QCDR,Structure,Y,83.33 - 94.11,94.12 - 98.58,98.59 - 99.99,--,--,--,--,100.00,No
Melanoma: Coordination of Care,138,Registry/QCDR,Process,Y,50.00 - 63.78,63.79 - 78.78,78.79 - 92.58,92.59 - 99.99,--,--,--,100.00,No
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Claims,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Registry/QCDR,Outcome,Y,72.29 - 87.48,87.49 - 96.05,96.06 - 99.30,99.31 - 99.99,--,--,--,100.00,No
Oncology: Medical and Radiation - Pain Intensity Quantified,143,EHR,Process,Y,78.10 - 88.23,88.24 - 95.23,95.24 - 97.33,97.34 - 98.36,98.37 - 99.56,99.57 - 99.99,--,100.00,Yes
Oncology: Medical and Radiation - Pain Intensity Quantified,143,Registry/QCDR,Process,Y,89.13 - 95.05,95.06 - 96.95,96.96 - 98.49,98.50 - 99.21,99.22 - 99.99,--,--,100.00,Yes
Oncology: Medical and Radiation - Plan of Care for Pain,144,Registry/QCDR,Process,Y,47.20 - 78.56,78.57 - 89.08,89.09 - 94.18,94.19 - 98.40,98.41 - 99.74,99.75 - 99.99,--,100.00,No
Radiology: Exposure Dose or Time Reported for Procedures Using Fluoroscopy,145,Claims,Process,Y,67.57 - 83.32,83.33 - 91.09,91.10 - 95.23,95.24 - 97.43,97.44 - 99.10,99.11 - 99.99,--,100.00,Yes
Radiology: Exposure Dose or Time Reported for Procedures Using Fluoroscopy,145,Registry/QCDR,Process,Y,74.14 - 88.42,88.43 - 95.07,95.08 - 98.19,98.20 - 99.55,99.56 - 99.99,--,--,100.00,Yes
"Radiology: Inappropriate Use of ""Probably Benign"" Assessment Category in Screening Mammograms",146,Claims,Process,Y,0.22 - 0.01,--,--,--,--,--,--,0.00,Yes
"Radiology: Inappropriate Use of ""Probably Benign"" Assessment Category in Screening Mammograms",146,Registry/QCDR,Process,Y,0.24 - 0.12,0.11 - 0.05,0.04 - 0.01,--,--,--,--,0.00,Yes
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Claims,Process,Y,75.44 - 87.17,87.18 - 93.74,93.75 - 97.13,97.14 - 99.99,--,--,--,100.00,Yes
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Registry/QCDR,Process,Y,93.00 - 97.94,97.95 - 99.99,--,--,--,--,--,100.00,Yes
Falls: Risk Assessment,154,Claims,Process,Y,98.28 - 99.99,--,--,--,--,--,--,100.00,Yes
Falls: Risk Assessment,154,Registry/QCDR,Process,Y,27.00 - 45.47,45.48 - 76.47,76.48 - 92.74,92.75 - 98.56,98.57 - 99.99,--,--,100.00,No
Falls: Plan of Care,155,Claims,Process,Y,63.86 - 95.93,95.94 - 99.99,--,--,--,--,--,100.00,Yes
Falls: Plan of Care,155,Registry/QCDR,Process,Y,67.35 - 86.91,86.92 - 95.19,95.20 - 98.28,98.29 - 99.99,--,--,--,100.00,Yes
HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis,160,EHR,Process,N,--,--,--,--,--,--,--,--,--
HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis,160,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Coronary Artery Bypass Graft (CABG): Prolonged Intubation,164,Registry/QCDR,Outcome,Y,11.36 - 8.86,8.85 - 7.70,7.69 - 7.09,7.08 - 5.80,5.79 - 4.45,4.44 - 3.04,3.03 - 1.57,<= 1.56,No
Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate,165,Registry/QCDR,Outcome,Y,0.69 - 0.01,--,--,--,--,--,--,0.00,Yes
Coronary Artery Bypass Graft (CABG): Stroke,166,Registry/QCDR,Outcome,Y,2.25 - 1.66,1.65 - 1.19,1.18 - 0.49,0.48 - 0.01,--,--,--,0.00,Yes
Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure,167,Registry/QCDR,Outcome,Y,3.70 - 2.87,2.86 - 2.28,2.27 - 1.87,1.86 - 1.40,1.39 - 0.92,0.91 - 0.01,--,0.00,Yes
Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration,168,Registry/QCDR,Outcome,Y,3.77 - 3.04,3.03 - 2.61,2.60 - 1.80,1.79 - 1.19,1.18 - 0.86,0.85 - 0.01,--,0.00,Yes
Rheumatoid Arthritis (RA): Tuberculosis Screening,176,Registry/QCDR,Process,Y,28.89 - 46.26,46.27 - 51.60,51.61 - 63.81,63.82 - 75.81,75.82 - 91.29,91.30 - 99.99,--,100.00,No
Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity,177,Registry/QCDR,Process,Y,51.70 - 72.29,72.30 - 86.57,86.58 - 94.63,94.64 - 99.99,--,--,--,100.00,No
Rheumatoid Arthritis (RA): Functional Status Assessment,178,Registry/QCDR,Process,Y,67.50 - 80.97,80.98 - 90.31,90.32 - 95.42,95.43 - 99.75,99.76 - 99.99,--,--,100.00,Yes
Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis,179,Registry/QCDR,Process,Y,43.24 - 66.18,66.19 - 81.72,81.73 - 94.27,94.28 - 99.99,--,--,--,100.00,No
Rheumatoid Arthritis (RA): Glucocorticoid Management,180,Registry/QCDR,Process,Y,49.40 - 75.26,75.27 - 86.57,86.58 - 94.61,94.62 - 99.07,99.08 - 99.99,--,--,100.00,No
Elder Maltreatment Screen and Follow-Up Plan,181,Claims,Process,Y,73.28 - 98.39,98.40 - 99.60,99.61 - 99.99,--,--,--,--,100.00,Yes
Elder Maltreatment Screen and Follow-Up Plan,181,Registry/QCDR,Process,Y,50.65 - 63.94,63.95 - 77.77,77.78 - 89.28,89.29 - 96.78,96.79 - 99.99,--,--,100.00,No
Functional Outcome Assessment,182,Claims,Process,Y,99.54 - 99.99,--,--,--,--,--,--,100.00,Yes
Functional Outcome Assessment,182,Registry/QCDR,Process,Y,90.88 - 94.09,94.10 - 95.59,95.60 - 99.41,99.42 - 99.99,--,--,--,100.00,Yes
"Colonoscopy Interval for Patients with a History of Adenomatous Polyps
- Avoidance of Inappropriate Use",185,Claims,Process,Y,98.77 - 99.99,--,--,--,--,--,--,100.00,Yes
"Colonoscopy Interval for Patients with a History of Adenomatous Polyps
- Avoidance of Inappropriate Use",185,Registry/QCDR,Process,Y,64.10 - 86.59,86.60 - 90.95,90.96 - 95.45,95.46 - 98.83,98.84 - 99.99,--,--,100.00,Yes
Stroke and Stroke Rehabilitation: Thrombolytic Therapy,187,Registry/QCDR,Process,Y,88.89 - 96.48,96.49 - 99.99,--,--,--,--,--,100.00,Yes
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,EHR,Outcome,Y,85.80 - 90.90,90.91 - 93.74,93.75 - 95.73,95.74 - 97.00,97.01 - 97.89,97.90 - 98.82,98.83 - 99.99,100.00,No
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,Registry/QCDR,Outcome,Y,94.53 - 97.05,97.06 - 98.98,98.99 - 99.99,--,--,--,--,100.00,Yes
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures,192,EHR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures,192,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,Claims,Process,Y,91.76 - 96.24,96.25 - 98.17,98.18 - 99.99,--,--,--,--,100.00,Yes
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,Registry/QCDR,Process,Y,97.83 - 99.89,99.90 - 99.99,--,--,--,--,--,100.00,Yes
"HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis",205,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Knee Impairments,217,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Hip Impairments,218,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Foot or Ankle Impairments,219,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Lumbar Impairments,220,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Shoulder Impairments,221,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Functional Status Change for Patients with Elbow, Wrist or Hand Impairments",222,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with General Orthopaedic Impairments,223,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Radiology: Reminder System for Screening Mammograms,225,Claims,Structure,Y,99.34 - 99.99,--,--,--,--,--,--,100.00,Yes
Radiology: Reminder System for Screening Mammograms,225,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100.00,Yes
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,CMS Web Interface,Process,N,--,--,--,--,--,--,--,--,--
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Claims,Process,Y,97.62 - 99.20,99.21 - 99.99,--,--,--,--,--,100.00,Yes
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,EHR,Process,Y,73.68 - 83.30,83.31 - 88.05,88.06 - 91.29,91.30 - 93.82,93.83 - 96.02,96.03 - 98.05,98.06 - 99.68,>= 99.69,No
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Registry/QCDR,Process,Y,87.18 - 92.06,92.07 - 95.40,95.41 - 97.64,97.65 - 99.33,99.34 - 99.99,--,--,100.00,Yes
Controlling High Blood Pressure,236,CMS Web Interface,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Controlling High Blood Pressure,236,Claims,Intermediate Outcome,Y,58.70 - 64.07,64.08 - 68.80,68.81 - 73.78,73.79 - 78.53,78.54 - 83.32,83.33 - 88.26,88.27 - 94.99,>= 95.00,No
Controlling High Blood Pressure,236,EHR,Intermediate Outcome,Y,51.70 - 57.08,57.09 - 61.13,61.14 - 64.84,64.85 - 68.41,68.42 - 72.21,72.22 - 76.41,76.42 - 82.17,>= 82.18,No
Controlling High Blood Pressure,236,Registry/QCDR,Intermediate Outcome,Y,52.05 - 59.99,60.00 - 65.44,65.45 - 70.58,70.59 - 76.79,76.80 - 84.64,84.65 - 93.17,93.18 - 99.99,100.00,No
Use of High-Risk Medications in the Elderly,238,EHR,Process,Y,7.93 - 4.70,4.69 - 2.68,2.67 - 1.31,1.30 - 0.53,0.52 - 0.03,0.02 - 0.01,--,0.00,Yes
Use of High-Risk Medications in the Elderly,238,Registry/QCDR,Process,Y,0.62 - 0.29,0.28 - 0.14,0.13 - 0.01,--,--,--,--,0.00,Yes
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents,239,EHR,Process,Y,26.19 - 29.39,29.40 - 31.47,31.48 - 32.78,32.79 - 33.81,33.82 - 38.62,38.63 - 47.51,47.52 - 65.51,>= 65.52,No
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents,239,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Childhood Immunization Status,240,EHR,Process,Y,9.09 - 14.41,14.42 - 19.99,20.00 - 26.66,26.67 - 30.61,30.62 - 36.94,36.95 - 42.02,42.03 - 49.99,>= 50.00,No
Childhood Immunization Status,240,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cardiac Rehabilitation Patient Referral from an Outpatient Setting,243,Registry/QCDR,Process,Y,8.11 - 11.87,11.88 - 14.75,14.76 - 17.22,17.23 - 20.72,20.73 - 24.31,24.32 - 30.84,30.85 - 44.69,>= 44.70,No
Barrett's Esophagus,249,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Barrett's Esophagus,249,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Radical Prostatectomy Pathology Reporting,250,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Radical Prostatectomy Pathology Reporting,250,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,Claims,Process,N,--,--,--,--,--,--,--,--,--
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,Registry/QCDR,Process,Y,74.42 - 80.94,80.95 - 85.48,85.49 - 88.88,88.89 - 91.99,92.00 - 95.30,95.31 - 97.51,97.52 - 99.99,100.00,No
Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure,255,Claims,Process,N,--,--,--,--,--,--,--,--,--
Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure,255,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of Open Repair of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7),258,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post Operative Day #2),259,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)",260,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness,261,Claims,Process,N,--,--,--,--,--,--,--,--,--
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness,261,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Image Confirmation of Successful Excision of Image-Localized Breast Lesion,262,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Sentinel Lymph Node Biopsy for Invasive Breast Cancer,264,Registry/QCDR,Process,Y,97.96 - 98.97,98.98 - 99.99,--,--,--,--,--,100.00,Yes
Biopsy Follow-Up,265,Registry/QCDR,Process,Y,61.20 - 84.74,84.75 - 95.86,95.87 - 99.51,99.52 - 99.99,--,--,--,100.00,Yes
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,Claims,Process,N,--,--,--,--,--,--,--,--,--
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,Registry/QCDR,Process,Y,28.43 - 32.68,32.69 - 45.44,45.45 - 70.39,70.40 - 95.99,96.00 - 99.06,99.07 - 99.99,--,100.00,No
Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury - Bone Loss Assessment,271,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy,275,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Sleep Apnea: Severity Assessment at Initial Diagnosis,277,Registry/QCDR,Process,Y,68.26 - 81.02,81.03 - 90.43,90.44 - 99.70,99.71 - 99.99,--,--,--,100.00,Yes
Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy,279,Registry/QCDR,Process,Y,88.89 - 94.99,95.00 - 98.58,98.59 - 99.99,--,--,--,--,100.00,Yes
Dementia: Cognitive Assessment,281,EHR,Process,Y,5.91 - 13.32,13.33 - 27.26,27.27 - 44.64,44.65 - 59.99,60.00 - 74.54,74.55 - 88.56,88.57 - 96.21,>= 96.22,No
Dementia: Cognitive Assessment,281,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Dementia: Functional Status Assessment,282,Registry/QCDR,Process,Y,57.14 - 81.24,81.25 - 97.00,97.01 - 99.79,99.80 - 99.99,--,--,--,100.00,Yes
Dementia: Neuropsychiatric Symptom Assessment,283,Registry/QCDR,Process,Y,59.38 - 88.45,88.46 - 98.07,98.08 - 99.99,--,--,--,--,100.00,Yes
Dementia: Counseling Regarding Safety Concerns,286,Registry/QCDR,Process,Y,62.13 - 80.35,80.36 - 90.39,90.40 - 98.20,98.21 - 99.99,--,--,--,100.00,Yes
Dementia: Caregiver Education and Support,288,Registry/QCDR,Process,Y,59.38 - 77.77,77.78 - 89.99,90.00 - 98.25,98.26 - 99.99,--,--,--,100.00,Yes
Parkinson's Disease: Psychiatric Symptoms Assessment for Patients with Parkinson's Disease,290,Registry/QCDR,Process,Y,86.49 - 92.55,92.56 - 96.96,96.97 - 99.10,99.11 - 99.99,--,--,--,100.00,Yes
Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment,291,Registry/QCDR,Process,Y,85.49 - 94.99,95.00 - 99.99,--,--,--,--,--,100.00,Yes
Parkinson's Disease: Rehabilitative Therapy Options,293,Registry/QCDR,Process,Y,67.03 - 82.94,82.95 - 94.28,94.29 - 99.99,--,--,--,--,100.00,Yes
Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery,303,Registry/QCDR,Outcome,Y,45.11 - 70.87,70.88 - 79.58,79.59 - 85.97,85.98 - 92.09,92.10 - 99.02,99.03 - 99.99,--,100.00,No
Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery,304,Registry/QCDR,Outcome,Y,50.41 - 73.41,73.42 - 81.24,81.25 - 88.94,88.95 - 95.66,95.67 - 99.53,99.54 - 99.99,--,100.00,No
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment,305,EHR,Process,Y,0.31 - 0.41,0.42 - 0.63,0.64 - 1.00,1.01 - 1.27,1.28 - 2.07,2.08 - 3.78,3.79 - 6.66,>= 6.67,No
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment,305,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cervical Cancer Screening,309,EHR,Process,Y,9.43 - 16.07,16.08 - 22.78,22.79 - 30.40,30.41 - 38.45,38.46 - 47.04,47.05 - 56.79,56.80 - 71.14,>= 71.15,No
Cervical Cancer Screening,309,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Chlamydia Screening for Women,310,EHR,Process,Y,16.00 - 21.96,21.97 - 27.37,27.38 - 33.32,33.33 - 38.31,38.32 - 44.00,44.01 - 51.17,51.18 - 61.89,>= 61.90,No
Chlamydia Screening for Women,310,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Claims,Process,Y,34.94 - 45.73,45.74 - 57.54,57.55 - 72.83,72.84 - 88.90,88.91 - 97.87,97.88 - 99.99,--,100.00,No
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,EHR,Process,Y,19.55 - 24.13,24.14 - 28.18,28.19 - 32.23,32.24 - 36.64,36.65 - 42.08,42.09 - 50.38,50.39 - 73.18,>= 73.19,No
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Registry/QCDR,Process,Y,25.32 - 30.22,30.23 - 35.10,35.11 - 42.39,42.40 - 58.93,58.94 - 85.04,85.05 - 97.30,97.31 - 99.99,100.00,No
Falls: Screening for Future Fall Risk,318,CMS Web Interface,Process,N,--,--,--,--,--,--,--,--,--
Falls: Screening for Future Fall Risk,318,EHR,Process,Y,6.92 - 19.77,19.78 - 35.91,35.92 - 52.25,52.26 - 66.66,66.67 - 78.19,78.20 - 88.06,88.07 - 96.44,>= 96.45,No
Falls: Screening for Future Fall Risk,318,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Claims,Process,Y,91.53 - 97.21,97.22 - 99.99,--,--,--,--,--,100.00,Yes
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Registry/QCDR,Process,Y,84.92 - 89.32,89.33 - 93.32,93.33 - 96.06,96.07 - 97.75,97.76 - 99.00,99.01 - 99.99,--,100.00,Yes
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients,322,Registry/QCDR,Efficiency,Y,1.90 - 0.01,--,--,--,--,--,--,0.00,Yes
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI),323,Registry/QCDR,Efficiency,Y,2.44 - 0.01,--,--,--,--,--,--,0.00,Yes
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",324,Registry/QCDR,Efficiency,Y,6.25 - 2.02,2.01 - 0.01,--,--,--,--,--,0.00,Yes
Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions,325,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,Claims,Process,Y,85.00 - 95.64,95.65 - 99.02,99.03 - 99.99,--,--,--,--,100.00,Yes
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,Registry/QCDR,Process,Y,69.55 - 75.52,75.53 - 78.97,78.98 - 83.32,83.33 - 88.09,88.10 - 94.36,94.37 - 99.99,--,100.00,No
Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10 g/dL,328,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis,329,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days,330,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adult Sinusitis: Antibiotic Prescribed for Acute Sinusitis (Overuse),331,Registry/QCDR,Process,Y,92.45 - 87.51,87.50 - 82.90,82.89 - 76.46,76.45 - 66.68,66.67 - 50.82,50.81 - 27.73,27.72 - 0.01,0.00,No
Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use),332,Registry/QCDR,Process,Y,93.33 - 96.19,96.20 - 97.61,97.62 - 98.41,98.42 - 99.50,99.51 - 99.99,--,--,100.00,Yes
Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse),333,Registry/QCDR,Efficiency,Y,2.50 - 0.95,0.94 - 0.23,0.22 - 0.01,--,--,--,--,0.00,Yes
Maternity Care: Elective Delivery or Early Induction Without Medical Indication at >= 37 and < 39 Weeks (Overuse),335,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Maternity Care: Post-Partum Follow-Up and Care Coordination,336,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Tuberculosis (TB) Prevention for Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier",337,Registry/QCDR,Process,Y,46.34 - 60.28,60.29 - 72.95,72.96 - 81.81,81.82 - 89.28,89.29 - 95.73,95.74 - 99.99,--,100.00,No
HIV Viral Load Suppression,338,Registry/QCDR,Outcome,Y,75.80 - 81.05,81.06 - 85.57,85.58 - 88.45,88.46 - 94.61,94.62 - 97.23,97.24 - 99.99,--,100.00,No
HIV Medical Visit Frequency,340,Registry/QCDR,Process,Y,48.97 - 52.85,52.86 - 69.08,69.09 - 82.25,82.26 - 86.20,86.21 - 92.85,92.86 - 95.91,95.92 - 99.99,100.00,No
Pain Brought Under Control Within 48 Hours,342,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
Screening Colonoscopy Adenoma Detection Rate,343,Registry/QCDR,Outcome,Y,30.35 - 34.87,34.88 - 39.33,39.34 - 42.53,42.54 - 46.81,46.82 - 51.08,51.09 - 61.21,61.22 - 86.83,>= 86.84,No
"Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2)",344,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS),345,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Endarterectomy (CEA),346,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital,347,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate,348,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy,350,Registry/QCDR,Process,Y,97.32 - 99.99,--,--,--,--,--,--,100.00,Yes
Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation,351,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet,352,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report,353,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Anastomotic Leak Intervention,354,Registry/QCDR,Outcome,Y,3.66 - 3.24,3.23 - 0.80,0.79 - 0.01,--,--,--,--,0.00,Yes
Unplanned Reoperation within the 30 Day Postoperative Period,355,Registry/QCDR,Outcome,Y,3.18 - 2.18,2.17 - 1.19,1.18 - 0.19,0.18 - 0.01,--,--,--,0.00,Yes
Unplanned Hospital Readmission within 30 Days of Principal Procedure,356,Registry/QCDR,Outcome,Y,5.00 - 3.31,3.30 - 2.01,2.00 - 0.01,--,--,--,--,0.00,Yes
Surgical Site Infection (SSI),357,Registry/QCDR,Outcome,Y,3.39 - 2.26,2.25 - 0.89,0.88 - 0.01,--,--,--,--,0.00,Yes
Patient-Centered Surgical Risk Assessment and Communication,358,Registry/QCDR,Process,Y,17.39 - 61.78,61.79 - 89.99,90.00 - 98.21,98.22 - 99.99,--,--,--,100.00,Yes
Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies,360,Registry/QCDR,Process,Y,30.10 - 59.99,60.00 - 85.87,85.88 - 98.43,98.44 - 99.99,--,--,--,100.00,Yes
Optimizing Patient Exposure to Ionizing Radiation: Reporting to a Radiation Dose Index Registry,361,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100.00,Yes
Optimizing Patient Exposure to Ionizing Radiation: Computed Tomography (CT) Images Available for Patient Follow-up and Comparison Purposes,362,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100.00,Yes
Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines,364,Registry/QCDR,Process,Y,59.02 - 93.24,93.25 - 97.64,97.65 - 99.83,99.84 - 99.99,--,--,--,100.00,Yes
ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication,366,EHR,Process,Y,26.67 - 29.16,29.17 - 33.95,33.96 - 37.22,37.23 - 43.32,43.33 - 49.50,49.51 - 54.54,54.55 - 65.90,>= 65.91,No
ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication,366,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Depression Remission at Twelve Months,370,CMS Web Interface,Outcome,N,--,--,--,--,--,--,--,--,--
Depression Remission at Twelve Months,370,EHR,Outcome,Y,2.05 - 2.62,2.63 - 3.51,3.52 - 4.30,4.31 - 5.31,5.32 - 7.26,7.27 - 9.51,9.52 - 15.14,>= 15.15,No
Depression Remission at Twelve Months,370,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Depression Utilization of the PHQ-9 Tool,371,EHR,Process,Y,3.69 - 5.92,5.93 - 8.69,8.70 - 12.37,12.38 - 16.21,16.22 - 21.56,21.57 - 29.86,29.87 - 42.98,>= 42.99,No
Depression Utilization of the PHQ-9 Tool,371,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Maternal Depression Screening,372,EHR,Process,N,--,--,--,--,--,--,--,--,--
Maternal Depression Screening,372,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Closing the Referral Loop: Receipt of Specialist Report,374,EHR,Process,Y,7.52 - 14.47,14.48 - 25.16,25.17 - 35.96,35.97 - 47.53,47.54 - 59.87,59.88 - 73.96,73.97 - 90.49,>= 90.50,No
Closing the Referral Loop: Receipt of Specialist Report,374,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Functional Status Assessment for Total Knee Replacement,375,EHR,Process,Y,4.80 - 9.42,9.43 - 14.54,14.55 - 20.26,20.27 - 25.44,25.45 - 34.74,34.75 - 53.69,53.70 - 76.46,>= 76.47,No
Functional Status Assessment for Total Knee Replacement,375,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Functional Status Assessment for Total Hip Replacement,376,EHR,Process,Y,4.76 - 8.50,8.51 - 11.10,11.11 - 17.44,17.45 - 27.90,27.91 - 33.32,33.33 - 40.61,40.62 - 63.48,>= 63.49,No
Functional Status Assessment for Total Hip Replacement,376,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Functional Status Assessments for Congestive Heart Failure,377,EHR,Process,N,--,--,--,--,--,--,--,--,--
Functional Status Assessments for Congestive Heart Failure,377,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Children Who Have Dental Decay or Cavities,378,EHR,Outcome,Y,0.45 - 0.08,0.07 - 0.01,--,--,--,--,--,0.00,Yes
Children Who Have Dental Decay or Cavities,378,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists",379,EHR,Process,Y,0.32 - 0.57,0.58 - 0.77,0.78 - 1.42,1.43 - 2.23,2.24 - 3.47,3.48 - 5.12,5.13 - 9.04,>= 9.05,No
"Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists",379,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment,382,EHR,Process,Y,4.21 - 8.05,8.06 - 12.89,12.90 - 15.26,15.27 - 22.57,22.58 - 29.24,29.25 - 36.11,36.12 - 55.05,>= 55.06,No
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment,382,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Adherence to Antipsychotic Medications For Individuals with Schizophrenia,383,Registry/QCDR,Intermediate Outcome,Y,58.00 - 69.22,69.23 - 84.37,84.38 - 88.47,88.48 - 97.60,97.61 - 99.99,--,--,100.00,No
Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery,384,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery,385,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences,386,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users,387,Registry/QCDR,Process,Y,0.38 - 0.45,0.46 - 0.70,0.71 - 0.80,0.81 - 1.12,1.13 - 1.40,1.41 - 1.60,1.61 - 2.86,>= 2.87,No
Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy),388,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
Cataract Surgery: Difference Between Planned and Final Refraction,389,Registry/QCDR,Outcome,Y,78.06 - 91.99,92.00 - 97.12,97.13 - 99.40,99.41 - 99.99,--,--,--,100.00,No
Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options,390,Registry/QCDR,Process,Y,67.44 - 88.51,88.52 - 96.87,96.88 - 99.99,--,--,--,--,100.00,Yes
Follow-Up After Hospitalization for Mental Illness (FUH),391,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HRS-12: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation,392,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"HRS-9: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision",393,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Immunizations for Adolescents,394,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Claims,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
Lung Cancer Reporting (Resection Specimens),396,Claims,Outcome,N,--,--,--,--,--,--,--,--,--
Lung Cancer Reporting (Resection Specimens),396,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
Melanoma Reporting,397,Claims,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
Melanoma Reporting,397,Registry/QCDR,Outcome,Y,91.96 - 99.99,--,--,--,--,--,--,100.00,No
Optimal Asthma Control,398,Registry/QCDR,Outcome,Y,24.05 - 52.69,52.70 - 68.44,68.45 - 89.73,89.74 - 98.42,98.43 - 99.99,--,--,100.00,No
One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk,400,Registry/QCDR,Process,Y,1.17 - 1.76,1.77 - 2.35,2.36 - 4.46,4.47 - 12.62,12.63 - 21.43,21.44 - 29.21,29.22 - 59.51,>= 59.52,No
Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis,401,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Tobacco Use and Help with Quitting Among Adolescents,402,Registry/QCDR,Process,Y,85.98 - 91.02,91.03 - 94.11,94.12 - 96.05,96.06 - 97.61,97.62 - 98.86,98.87 - 99.99,--,100.00,Yes
Adult Kidney Disease: Referral to Hospice,403,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Anesthesiology Smoking Abstinence,404,Registry/QCDR,Intermediate Outcome,Y,40.23 - 50.67,50.68 - 57.74,57.75 - 63.44,63.45 - 69.73,69.74 - 74.82,74.83 - 82.83,82.84 - 93.87,>= 93.88,No
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Claims,Process,Y,11.11 - 4.56,4.55 - 0.96,0.95 - 0.01,--,--,--,--,0.00,Yes
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Registry/QCDR,Process,Y,12.64 - 7.87,7.86 - 2.42,2.41 - 0.23,0.22 - 0.01,--,--,--,0.00,Yes
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,Claims,Process,Y,69.41 - 48.01,48.00 - 40.19,40.18 - 21.75,21.74 - 3.47,3.46 - 2.45,2.44 - 0.01,--,0.00,No
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,Registry/QCDR,Process,Y,14.94 - 5.98,5.97 - 3.65,3.64 - 0.06,0.05 - 0.01,--,--,--,0.00,Yes
Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia,407,Claims,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia,407,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Opioid Therapy Follow-up Evaluation,408,Registry/QCDR,Process,Y,61.67 - 86.97,86.98 - 97.19,97.20 - 99.88,99.89 - 99.99,--,--,--,100.00,Yes
Clinical Outcome Post Endovascular Stroke Treatment,409,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Psoriasis: Clinical Response to Oral Systemic or Biologic Medications,410,Claims,Outcome,N,--,--,--,--,--,--,--,--,--
Psoriasis: Clinical Response to Oral Systemic or Biologic Medications,410,Registry/QCDR,Outcome,Y,23.26 - 37.49,37.50 - 49.99,50.00 - 61.89,61.90 - 72.72,72.73 - 87.49,87.50 - 96.91,96.92 - 99.99,100.00,No
Depression Remission at Six Months,411,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Documentation of Signed Opioid Treatment Agreement,412,Registry/QCDR,Process,Y,63.69 - 88.98,88.99 - 97.65,97.66 - 99.70,99.71 - 99.99,--,--,--,100.00,Yes
Door to Puncture Time for Endovascular Stroke Treatment,413,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Evaluation or Interview for Risk of Opioid Misuse,414,Registry/QCDR,Process,Y,88.55 - 98.59,98.60 - 99.99,--,--,--,--,--,100.00,Yes
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,Claims,Efficiency,Y,95.92 - 99.99,--,--,--,--,--,--,100.00,Yes
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,Registry/QCDR,Efficiency,Y,63.40 - 69.99,70.00 - 76.33,76.34 - 80.45,80.46 - 83.53,83.54 - 86.72,86.73 - 89.80,89.81 - 98.69,>= 98.70,No
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,Claims,Efficiency,N,--,--,--,--,--,--,--,--,--
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,Registry/QCDR,Efficiency,Y,46.34 - 40.01,40.00 - 34.70,34.69 - 28.36,28.35 - 22.32,22.31 - 18.76,18.75 - 14.82,14.81 - 9.53,<= 9.52,No
Rate of Open Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) Where Patients Are Discharged Alive,417,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Osteoporosis Management in Women Who Had a Fracture,418,Claims,Process,N,--,--,--,--,--,--,--,--,--
Osteoporosis Management in Women Who Had a Fracture,418,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Overuse Of Neuroimaging For Patients With Primary Headache And A Normal Neurological Examination,419,Claims,Efficiency,N,--,--,--,--,--,--,--,--,--
Overuse Of Neuroimaging For Patients With Primary Headache And A Normal Neurological Examination,419,Registry/QCDR,Efficiency,Y,74.74 - 83.22,83.23 - 89.46,89.47 - 95.16,95.17 - 98.24,98.25 - 99.99,--,--,100.00,No
Varicose Vein Treatment with Saphenous Ablation: Outcome Survey,420,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate Assessment of Retrievable Inferior Vena Cava (IVC) Filters for Removal,421,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury,422,Claims,Process,N,--,--,--,--,--,--,--,--,--
Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury,422,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Perioperative Temperature Management,424,Registry/QCDR,Outcome,Y,98.75 - 99.55,99.56 - 99.77,99.78 - 99.89,99.90 - 99.99,--,--,--,100.00,Yes
Photodocumentation of Cecal Intubation,425,Claims,Process,Y,96.78 - 98.44,98.45 - 98.92,98.93 - 99.60,99.61 - 99.99,--,--,--,100.00,Yes
Photodocumentation of Cecal Intubation,425,Registry/QCDR,Process,Y,97.56 - 98.20,98.21 - 98.63,98.64 - 98.95,98.96 - 99.26,99.27 - 99.49,99.50 - 99.76,99.77 - 99.99,100.00,Yes
Pelvic Organ Prolapse: Preoperative Assessment of Occult Stress Urinary Incontinence,428,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy,429,Claims,Process,N,--,--,--,--,--,--,--,--,--
Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy,429,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy,430,Registry/QCDR,Process,Y,94.05 - 97.17,97.18 - 98.53,98.54 - 99.21,99.22 - 99.61,99.62 - 99.89,99.90 - 99.99,--,100.00,Yes
Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling,431,Registry/QCDR,Process,Y,32.47 - 48.00,48.01 - 64.29,64.30 - 77.26,77.27 - 86.53,86.54 - 92.93,92.94 - 97.69,97.70 - 99.99,100.00,No
Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair,432,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair,433,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion of Patients Sustaining a Ureter Injury at the Time of any Pelvic Organ Prolapse Repair,434,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Quality of Life Assessment For Patients With Primary Headache Disorders,435,Claims,Outcome,N,--,--,--,--,--,--,--,--,--
Quality of Life Assessment For Patients With Primary Headache Disorders,435,Registry/QCDR,Outcome,Y,1.69 - 2.86,2.87 - 3.69,3.70 - 12.37,12.38 - 49.26,49.27 - 92.36,92.37 - 99.99,--,100.00,No
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,Claims,Process,Y,87.11 - 94.69,94.70 - 97.75,97.76 - 99.06,99.07 - 99.70,99.71 - 99.99,--,--,100.00,Yes
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,Registry/QCDR,Process,Y,93.50 - 97.26,97.27 - 99.07,99.08 - 99.63,99.64 - 99.91,99.92 - 99.99,--,--,100.00,Yes
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure,437,Claims,Outcome,Y,2.86 - 1.13,1.12 - 0.01,--,--,--,--,--,0.00,Yes
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure,437,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,CMS Web Interface,Process,N,--,--,--,--,--,--,--,--,--
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,Registry/QCDR,Process,Y,69.07 - 77.22,77.23 - 86.89,86.90 - 95.99,96.00 - 99.99,--,--,--,100.00,Yes
Age Appropriate Screening Colonoscopy,439,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma: Biopsy Reporting Time - Pathologist to Clinician,440,Registry/QCDR,Process,Y,97.10 - 99.30,99.31 - 99.99,--,--,--,--,--,100.00,Yes
Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control),441,Registry/QCDR,Intermediate Outcome,Y,32.08 - 36.72,36.73 - 40.08,40.09 - 44.00,44.01 - 47.63,47.64 - 50.61,50.62 - 54.54,54.55 - 59.72,>= 59.73,No
Persistence of Beta-Blocker Treatment After a Heart Attack,442,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Recommended Cervical Cancer Screening in Adolescent Females,443,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Medication Management for People with Asthma,444,Registry/QCDR,Process,Y,91.67 - 95.99,96.00 - 97.18,97.19 - 98.43,98.44 - 99.99,--,--,--,100.00,Yes
Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG),445,Registry/QCDR,Outcome,Y,3.75 - 3.40,3.39 - 2.62,2.61 - 2.21,2.20 - 1.61,1.60 - 1.09,1.08 - 0.01,--,0.00,No
Operative Mortality Stratified by the Five STS-EACTS Mortality Categories,446,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate Workup Prior to Endometrial Ablation,448,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies,449,Registry/QCDR,Process,Y,94.59 - 97.95,97.96 - 99.99,--,--,--,--,--,100.00,Yes
Trastuzumab Received By Patients With AJCC Stage I (T1c) -  III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy,450,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
KRAS Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy,451,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies,452,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Proportion Receiving Chemotherapy in the Last 14 Days of Life,453,Registry/QCDR,Process,Y,15.00 - 10.43,10.42 - 9.19,9.18 - 8.00,7.99 - 7.42,7.41 - 7.31,7.30 - 6.48,6.47 - 0.01,0.00,No
Proportion of Patients who Died from Cancer with more than One Emergency Department Visit in the Last 30 Days of Life,454,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life,455,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion Not Admitted To Hospice,456,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Proportion Admitted to Hospice for less than 3 days,457,Registry/QCDR,Outcome,Y,15.38 - 15.10,15.09 - 12.51,12.50 - 10.01,10.00 - 9.65,9.64 - 6.46,6.45 - 4.33,4.32 - 0.01,0.00,No
Asthma Assessment and Classification,AAAAI11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Lung Function/Spirometry Evaluation,AAAAI12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Asthma Control: Minimal Important Difference Improvement,AAAAI17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Penicillin Allergy: Appropriate Removal or Confirmation,AAAAI18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Asthma: Pharmacologic Therapy for Persistent Asthma  Ambulatory Care Setting,AAAAI19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Asthma: Assessment of Asthma Control  Ambulatory Care Setting,AAAAI2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Allergen Immunotherapy Treatment: Allergen Specific Immunoglobulin E (IgE) Sensitivity Assessed and Documented Prior to Treatment,AAAAI5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation of Clinical Response to Allergen Immunotherapy within One Year,AAAAI6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Achievement of Projected Effective Dose of Standardized Allergens for Patient Treated With Allergen Immunotherapy for at Least One Year,AAAAI8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Assessment of Asthma Symptoms Prior to Administration of Allergen Immunotherapy Injection(s),AAAAI9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Psoriasis: Assessment of Psoriasis Disease Activity,AAD1,Registry/QCDR,Process,Y,10.49 - 18.41,18.42 - 25.12,25.13 - 35.23,35.24 - 42.88,42.89 - 57.07,57.08 - 74.54,74.55 - 99.99,100.00,No
Psoriasis: Screening for Psoriatic Arthritis,AAD2,Registry/QCDR,Process,Y,58.00 - 94.84,94.85 - 97.13,97.14 - 99.99,--,--,--,--,100.00,Yes
Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Superficial Basal Cell Carcinoma of the Trunk for Immune Competent Patients,AAD3,Registry/QCDR,Process,Y,1.58 - 0.01,--,--,--,--,--,--,0.00,Yes
Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Squamous Cell Carcinoma in Situ or Keratoacanthoma Type Squamous Cell Carcinoma 1 cm or Smaller on the Trunk,AAD4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Biopsy Reporting Time - Clinician to Patient,AAD5,Registry/QCDR,Process,Y,73.58 - 90.13,90.14 - 98.61,98.62 - 99.99,--,--,--,--,100.00,Yes
Diabetes/Pre-Diabetes Screening for Patients with DSP,AAN1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Falls screening,AAN10,Registry/QCDR,Process,Y,3.18 - 10.97,10.98 - 20.07,20.08 - 30.42,30.43 - 52.43,52.44 - 65.26,65.27 - 81.94,81.95 - 90.87,>= 90.88,No
Overuse of Opioid and Barbiturate Containing Medications for Primary Headache Disorders.,AAN11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Screening for Unhealthy Alcohol Use,AAN2,Registry/QCDR,Process,Y,42.45 - 46.26,46.27 - 47.02,47.03 - 49.31,49.32 - 52.30,52.31 - 53.46,53.47 - 55.12,55.13 - 59.18,>= 59.19,No
Screening for Psychiatric or Behavioral Health Disorders,AAN4,Registry/QCDR,Process,Y,27.63 - 42.66,42.67 - 59.99,60.00 - 74.35,74.36 - 83.99,84.00 - 94.11,94.12 - 98.18,98.19 - 99.79,>= 99.80,No
MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK,AAN5,Registry/QCDR,Process,Y,14.29 - 17.85,17.86 - 22.40,22.41 - 28.29,28.30 - 36.29,36.30 - 41.23,41.24 - 47.27,47.28 - 53.95,>= 53.96,No
Exercise and Appropriate Physical Activity Counseling for Patients with MS,AAN8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Querying about Symptoms of Autonomic Dysfunction,AAN9,Registry/QCDR,Process,Y,62.73 - 85.41,85.42 - 92.30,92.31 - 94.70,94.71 - 97.57,97.58 - 99.99,--,--,100.00,No
Otitis Media with Effusion: Systemic Antimicrobials  Avoidance of Inappropriate Use,AAO10,Registry/QCDR,Process,Y,94.62 - 97.57,97.58 - 98.57,98.58 - 99.99,--,--,--,--,100.00,Yes
Otitis Media with Effusion: Avoidance of Topical Intranasal Corticosteroids,AAO11,Registry/QCDR,Process,Y,99.58 - 99.99,--,--,--,--,--,--,100.00,Yes
Otitis Media with Effusion: Antihistamines or Decongestants  Avoidance of Inappropriate Use,AAO8,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Otitis Media with Effusion: Systemic Corticosteroids  Avoidance of Inappropriate Use,AAO9,Registry/QCDR,Process,Y,99.84 - 99.99,--,--,--,--,--,--,100.00,Yes
Intra-operative anesthesia safety,ABG1,Registry/QCDR,Outcome,Y,99.98 - 99.99,--,--,--,--,--,--,100.00,Yes
Patient Experience Survey,ABG12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Corneal Abrasion,ABG14,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
Dental Injury,ABG15,Registry/QCDR,Outcome,Y,0.01 - 0.01,--,--,--,--,--,--,0.00,Yes
Planned use of difficult airway equipment,ABG16,Registry/QCDR,Process,Y,56.93 - 64.22,64.23 - 72.37,72.38 - 78.82,78.83 - 83.74,83.75 - 90.42,90.43 - 94.91,94.92 - 99.83,>= 99.84,No
Pre-operative OSA assessment,ABG21,Registry/QCDR,Process,Y,42.29 - 52.84,52.85 - 70.10,70.11 - 87.29,87.30 - 91.76,91.77 - 95.66,95.67 - 99.96,99.97 - 99.99,100.00,No
Pre-Operative Screening for GERD,ABG28,Registry/QCDR,Process,Y,40.11 - 46.72,46.73 - 51.67,51.68 - 54.38,54.39 - 60.76,60.77 - 91.49,91.50 - 99.28,99.29 - 99.99,100.00,No
Pre-Operative Screening for Glaucoma,ABG29,Registry/QCDR,Process,Y,47.35 - 84.95,84.96 - 96.14,96.15 - 99.48,99.49 - 99.99,--,--,--,100.00,Yes
Pre-Operative Screening for PONV Risk,ABG30,Registry/QCDR,Process,Y,93.47 - 97.59,97.60 - 99.38,99.39 - 99.78,99.79 - 99.99,--,--,--,100.00,Yes
Pre-Operative Screening for Excessive Alcohol and Recreational Drug Use,ABG31,Registry/QCDR,Process,Y,99.34 - 99.77,99.78 - 99.99,--,--,--,--,--,100.00,Yes
Pain Related Quality of Life Interference,ABG32,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lower Body Functional Impairment (LBI),ABG33,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mood Assessment Screening and treatment,ABG34,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
PACU tracheal intubation Rate,ABG4,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
Composite Procedural Safety for All Vascular Access Procedures,ABG5,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
Immediate Adult Post-Operative Pain Management,ABG7,Registry/QCDR,Outcome,Y,97.38 - 98.45,98.46 - 99.14,99.15 - 99.71,99.72 - 99.84,99.85 - 99.99,--,--,100.00,Yes
Stroke intra or post PCI procedure in patients without CABG or other major surgeries during admission.,ACCCATH1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Cardiac Rehabilitation Patient Referral From an Inpatient Setting,ACCCATH13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
New requirement for dialysis post PCI in patients without CABG or other major surgeries during admission.,ACCCATH2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Vascular access site injury requiring treatment or major bleeding post PCI in patients without CABG or other major surgeries during admission.,ACCCATH3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Cardiac tamponade post PCI in patients without CABG or other major surgery during admission.,ACCCATH4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
STEMI patients receiving immediate PCI within 90 minutes.,ACCCATH5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
ACE-I or ARB prescribed at discharge for patients with an ejection fraction < 40% who had a PCI during the episode of care.,ACCCATH6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percutaneous Coronary Intervention (PCI): Post-procedural Optimal Medical Therapy,ACCCATH8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
PCI procedures that were inappropriate for patients with Acute Coronary Syndrome (ACS).,ACCCATH9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hypertension: Blood Pressure Control,ACCPIN1,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
CAD: Blood Pressure Control,ACCPIN2,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
HF: Patient Self Care Education,ACCPIN3,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
AFIB: CHA2DS2VASc Score Risk Score Documented,ACCPIN4,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding,ACEP21,Registry/QCDR,Process,Y,23.39 - 18.92,18.91 - 13.11,13.10 - 6.84,6.83 - 4.65,4.64 - 0.96,0.95 - 0.01,--,0.00,No
Appropriate Emergency Department Utilization of CT for Pulmonary Embolism,ACEP22,Registry/QCDR,Process,Y,8.00 - 14.99,15.00 - 18.95,18.96 - 22.72,22.73 - 26.55,26.56 - 29.46,29.47 - 36.66,36.67 - 50.58,>= 50.59,No
Pregnancy Test for Female Abdominal Pain Patients,ACEP24,Registry/QCDR,Process,Y,55.27 - 60.22,60.23 - 64.28,64.29 - 68.37,68.38 - 72.96,72.97 - 77.93,77.94 - 80.55,80.56 - 84.76,>= 84.77,No
Tobacco Use: Screening and Cessation Intervention,ACEP25,Registry/QCDR,Process,Y,63.33 - 67.15,67.16 - 71.87,71.88 - 74.99,75.00 - 78.56,78.57 - 81.81,81.82 - 85.70,85.71 - 90.31,>= 90.32,No
Sepsis Management: Septic Shock: Lactate Level Measurement,ACEP26,Registry/QCDR,Process,Y,79.02 - 81.02,81.03 - 84.72,84.73 - 87.74,87.75 - 90.68,90.69 - 92.97,92.98 - 94.63,94.64 - 96.42,>= 96.43,No
Sepsis Management: Septic Shock: Antibiotics Ordered,ACEP27,Registry/QCDR,Process,Y,56.25 - 61.89,61.90 - 69.56,69.57 - 80.27,80.28 - 85.70,85.71 - 89.28,89.29 - 93.54,93.55 - 96.96,>= 96.97,No
Sepsis Management: Septic Shock: Fluid Resuscitation,ACEP28,Registry/QCDR,Process,Y,79.17 - 84.32,84.33 - 85.70,85.71 - 88.61,88.62 - 90.31,90.32 - 93.54,93.55 - 94.63,94.64 - 95.50,>= 95.51,No
Sepsis Management: Septic Shock: Repeat Lactate Level Measurement,ACEP29,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Sepsis Management: Septic Shock: Lactate Clearance Rate  10%,ACEP30,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Emergency Medicine: Appropriate Foley Catheter Use in the Emergency Department,ACEP31,Registry/QCDR,Process,Y,42.73 - 51.80,51.81 - 59.08,59.09 - 63.36,63.37 - 69.62,69.63 - 74.67,74.68 - 88.68,88.69 - 91.61,>= 91.62,No
Sepsis Management: Septic Shock: Blood Cultures Ordered,ACEP48,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Emergency Medicine: Appropriate Use of Imaging for Recurrent Renal Colic,ACEP49,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
High Risk Pneumococcal Vaccination,ACPGR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Tdap (Tetanus, Diphtheria, Acellular Pertussis) Vaccination",ACPGR2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy,ACPGR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Gout: Serum Urate Target,ACR7,Registry/QCDR,Intermediate Outcome,Y,20.83 - 24.55,24.56 - 31.81,31.82 - 38.09,38.10 - 41.45,41.46 - 44.61,44.62 - 47.82,47.83 - 65.24,>= 65.25,No
CT Colonography True Positive Rate,ACRAD1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
CT Colonography Clinically Significant Extracolonic Findings (Inverse Measure),ACRAD2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lung Cancer Screening Cancer Detection Rate (CDR),ACRAD21,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lung Cancer Screening Positive Predictive Value (PPV),ACRAD22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lung Cancer Screening Abnormal Interpretation Rate,ACRAD23,Registry/QCDR,Outcome,Y,21.25 - 20.17,20.16 - 18.09,18.08 - 17.25,17.24 - 15.33,15.32 - 13.05,13.04 - 11.88,11.87 - 6.91,<= 6.90,No
Appropriate venous access for hemodialysis,ACRAD26,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Uterine artery embolization technique: Documentation of angiographic endpoints and interrogation of ovarian arteries,ACRAD27,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of early peristomal infection following fluoroscopically guided gastrostomy tube placement,ACRAD28,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of percutaneous nephrostomy tube replacement within 30 days secondary to dislodgement,ACRAD29,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening Mammography Cancer Detection Rate (CDR),ACRAD3,Registry/QCDR,Outcome,Y,0.18 - 0.24,0.25 - 0.30,0.31 - 0.41,0.42 - 0.47,0.48 - 0.51,0.52 - 0.58,0.59 - 0.75,>= 0.76,No
Rate of Inadequate Percutaneous Image-Guided Biopsy,ACRAD30,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Percent of CT Abdomen-pelvis exams with contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level.,ACRAD31,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
Percent of CT Chest exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level.,ACRAD32,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
Percent of CT Head/Brain exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level,ACRAD33,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
"Screening Mammography Abnormal Interpretation Rate (Recall Rate)
(inverse Measure)",ACRAD5,Registry/QCDR,Outcome,Y,12.96 - 10.94,10.93 - 9.54,9.53 - 7.87,7.86 - 7.04,7.03 - 5.98,5.97 - 3.53,3.52 - 1.93,<= 1.92,No
"Screening Mammography Positive Predictive Value 2 (PPV2 - Biopsy
Recommended)",ACRAD6,Registry/QCDR,Outcome,Y,20.00 - 21.61,21.62 - 23.07,23.08 - 26.08,26.09 - 29.89,29.90 - 31.99,32.00 - 35.58,35.59 - 37.15,>= 37.16,No
Screening Mammography Node Negativity Rate,ACRAD7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening Mammography Minimal Cancer Rate,ACRAD8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Preoperative Composite,ACS15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Preventative Care and Screening: Tobacco Screening and Cessation Intervention,ACS16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Preoperative Key Medications Review for Anticoagulation Medication,ACS17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Frailty Evaluation,ACS18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Intraoperative Composite,ACS19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Optimal Postoperative Communication Plan and Patient Care Coordination Composite,ACS20,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Post-Acute Recovery Composite,ACS21,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Reoperation within the 30 Day Postoperative Period,ACS22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Hospital Readmission within 30 Days of Principal Procedure,ACS23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Ventral Hernia Repair: Surgical Site Occurrence Requiring Procedural Intervention within the 30 Day Postoperative Period,AHSQC1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Hospital Readmission or Observation Visit within the 30 Day Postoperative Period,AHSQC2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Abdominal Wall Reconstruction Surgical Site Occurrence Requiring Procedural Intervention within the 30 Day Postoperative Period,AHSQC6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Abdominal Wall Reconstruction Preoperative Diabetes Assessment,AHSQC7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Ventral Hernia Repair: Biologic Mesh Prosthesis Use in Low Risk Patients,AHSQC8,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Ventral Hernia Repair: Pain and Functional Status Assessment,AHSQC9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Hip Arthroplasty: Postoperative Complications within 90 Days Following the Procedure,AJRR1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Hip Arthroplasty: Health and Functional Improvement,AJRR2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Hip Arthroplasty: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy,AJRR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hip Arthroplasty: Venous Thromboembolic and Cardiovascular Risk Evaluation,AJRR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Comprehensive Diabetic Foot Examination,APMA1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Coronary Artery Bypass Graft (CABG): Prolonged Intubation - INVERSE MEASURE,AQI18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
New Corneal Injury Not Diagnosed in the Postanesthesia Care Unit/Recovery Area after Anesthesia Care,AQI28,Registry/QCDR,Outcome,Y,99.98 - 99.99,--,--,--,--,--,--,100.00,Yes
Prevention of Post-Operative Vomiting (POV)  Combination Therapy (Pediatrics),AQI29,Registry/QCDR,Process,Y,88.72 - 93.85,93.86 - 96.66,96.67 - 98.04,98.05 - 98.87,98.88 - 99.75,99.76 - 99.99,--,100.00,Yes
Anesthesia Safety,AQI30,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Postanesthesia Care Unit (PACU) Re-intubation Rate - INVERSE MEASURE,AQI31,Registry/QCDR,Intermediate Outcome,Y,0.41 - 0.12,0.11 - 0.05,0.04 - 0.02,0.01 - 0.01,--,--,--,0.00,No
Procedural Safety for Central Line Placement,AQI32,Registry/QCDR,Intermediate Outcome,Y,99.94 - 99.99,--,--,--,--,--,--,100.00,Yes
Perioperative Cardiac Arrest - INVERSE MEASURE,AQI34,Registry/QCDR,Outcome,Y,0.08 - 0.04,0.03 - 0.02,0.01 - 0.01,--,--,--,--,0.00,No
Perioperative Mortality Rate - INVERSE MEASURE,AQI35,Registry/QCDR,Outcome,Y,0.02 - 0.01,--,--,--,--,--,--,0.00,Yes
Surgical Safety Checklist  Applicable Safety Checks Completed Before Induction of Anesthesia,AQI37,Registry/QCDR,Process,Y,99.89 - 99.97,99.98 - 99.99,--,--,--,--,--,100.00,Yes
Coronary Artery Bypass Graft (CABG): Stroke - INVERSE MEASURE,AQI41,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Coronary Artery Bypass Graft (CABG): Post-Operative Renal Failure - INVERSE MEASURE,AQI42,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Anesthesia: Patient Experience Survey,AQI48,Registry/QCDR,Process,Y,57.81 - 89.36,89.37 - 96.92,96.93 - 99.81,99.82 - 99.99,--,--,--,100.00,Yes
Adherence to Blood Conservation Guidelines for Cardiac Operations using Cardiopulmonary Bypass (CPB)  Composite,AQI49,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Application of Lung-Protective Ventilation during General Anesthesia,AQI50,Registry/QCDR,Intermediate Outcome,Y,99.15 - 99.79,99.80 - 99.99,--,--,--,--,--,100.00,Yes
Assessment of Patients for Obstructive Sleep Apnea,AQI51,Registry/QCDR,Process,Y,86.41 - 93.98,93.99 - 98.28,98.29 - 99.51,99.52 - 99.90,99.91 - 99.96,99.97 - 99.99,--,100.00,Yes
Treatment of Hyperglycemia with Insulin,AQI52,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Patient Report of Urinary function after treatment,AQUA10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Patient Report of Sexual function after treatment,AQUA11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Benign Prostate Hyperplasia: IPSS improvement after diagnosis,AQUA12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Stress Urinary Incontinence (SUI): Revision surgery within 12 months of incontinence procedure,AQUA13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Stones: Repeat Shock Wave Lithotripsy (SWL) within 6 months of treatment,AQUA14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Stones: Urinalysis documented 30 days before surgical stone procedures,AQUA15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Muscle Invasive Bladder Cancer: Repeat Transurethal Resection of Bladder Tumor (TURBT) for T1 disease,AQUA16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Muscle Invasive Bladder Cancer: Initiation of BCG 3 months of diagnosis of high-grade T1 bladder cancer and/or CIS,AQUA17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Muscle Invasive Bladder Cancer: Early surveillance cystoscopy within 4 months of initial diagnosis,AQUA18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys,AQUA3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hypogonadism: Testosterone lab ordered/reported within 6 months of starting testosterone replacement,AQUA4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Benign Prostate Hyperplasia: Do not order creatinine lab for patients,AQUA5,Registry/QCDR,Process,Y,3.60 - 2.95,2.94 - 0.40,0.39 - 0.01,--,--,--,--,0.00,Yes
Benign Prostate Hyperplasia: Do not order upper-tract imaging,AQUA6,Registry/QCDR,Process,Y,5.40 - 2.64,2.63 - 0.32,0.31 - 0.01,--,--,--,--,0.00,Yes
Hospital re-admissions/complications within 30 days of TRUS Biopsy,AQUA8,Registry/QCDR,Outcome,Y,5.13 - 4.23,4.22 - 3.22,3.21 - 2.64,2.63 - 1.02,1.01 - 0.70,0.69 - 0.01,--,0.00,Yes
Risk Standardized Mortality Rate within 30 days following Trauma Operation,ARCO10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation within 45 minutes of ED Arrival,ARCO11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Venous Thromboembolism (VTE) Prophylaxis,ARCO12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Ischemic stroke patients management -,ARCO13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Gout: ULT Therapy,ARCO14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Antipsychotic Use in Persons with Dementia,ARCO3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Laboratory Investigation for Secondary Causes of Fracture,ARCO7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Surgeon assessment for hereditary cause of breast cancer,ASBS1,Registry/QCDR,Process,Y,99.12 - 99.99,--,--,--,--,--,--,100.00,Yes
Management of the axilla in breast cancer patients undergoing breast conserving surgery with a positive sentinel node biopsy,ASBS10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Unplanned 30 day re-operation after mastectomy,ASBS7,Registry/QCDR,Outcome,Y,96.99 - 98.29,98.30 - 98.58,98.59 - 99.99,--,--,--,--,100.00,Yes
Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients,ASNC1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT-MPI studies meeting appropriate use criteria,ASNC13,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
PET-MPI studies meeting appropriate use criteria,ASNC14,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
SPECT-MPI studies not Equivocal,ASNC17,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
PET-MPI studies not Equivocal,ASNC18,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Imaging Protocols for SPECT and PET MPI studies - Use of stress only protocol,ASNC19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI),ASNC2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT-MPI studies performed without the use of thallium,ASNC20,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study appropriate imaging protocol selection for morbidly obese patients,ASNC21,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
SPECT and PET MPI studies reporting Left Ventricular Ejection Fraction,ASNC22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study clinical utilization of Attenuation Correction image acquisition,ASNC23,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study utilization of exercise as a stressor,ASNC24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study adequate exercise testing performed,ASNC25,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
"Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",ASNC3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Utilization of standardized nomenclature and reporting for nuclear cardiology imaging studies,ASNC4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Transfusion goal of hematocrit less than 30 or hemoglobin less than 10.,ASPIRE13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Avoiding intraoperative hypotension,ASPIRE16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoiding myocardial Injury,ASPIRE18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Avoiding acute kidney injury,ASPIRE19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Train of Four Monitor Documented After Last Dose of Non-depolarizing Neuromuscular Blocker,ASPIRE2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoiding medication overdose,ASPIRE22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Administration of Neostigmine before Extubation for Cases with Nondepolarizing Neuromuscular Blockade,ASPIRE3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Administration of insulin or glucose recheck for patients with hyperglycemia,ASPIRE4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoiding excessively high tidal volumes during positive pressure ventilation,ASPIRE6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Core temperature measurement for all general anesthetics,ASPIRE8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Breast Reconstruction: Return to OR,ASPS5,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Breast Reconstruction: Flap Loss,ASPS6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Complete assessment and evaluation of patients pelvic organ prolapse prior to surgical repair,AUGS1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Preoperative utilization of pessary prior to Pelvic Organ Prolapse surgery,AUGS2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Preoperative assessment of sexual function prior to pelvic organ prolapse repair,AUGS3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Performing an intraoperative rectal examination at the time of prolapse repair,AUGS4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Performing vaginal apical suspension at the time of hysterectomy to address pelvic organ prolapse,AUGS5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Route of Hysterectomy,AUGS6,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Documentation that conservative management was offered prior to fecal incontinence surgery or procedures.,AUGS7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation of weight loss counseling prior to surgery for stress urinary incontinence procedures for obese women,AUGS8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Over-utilization of synthetic mesh in the posterior compartment,AUGS9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Reported Comprehensive Assessment of Safety,BIVARUS27,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
Patient Reported Experience and Care Coordination,BIVARUS28,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
Patient Reported Pain Treatment Effectiveness,BIVARUS30,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Reported Communication and Care Coordination,BIVARUS31,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Reported Care Team Communication,BIVARUS32,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
Preoperative notification of risk of developing ischemic optic neuropathy (ION) during prone spine procedures,BNS1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Topic: Turnaround time (TAT) for standard biopsies,CAP1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Carcinoma of the Endometrium Completed,CAP2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Invasive Carcinoma of Renal Tubular Origin Completed,CAP3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Carcinoma of the Intrahepatic Bile Ducts Completed,CAP4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Hepatocellular Carcinoma Completed,CAP5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Carcinoma of the Pancreas Completed,CAP6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after Total Knee Arthroplasty,CCOME1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after Total Hip Arthroplasty,CCOME2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after Total Shoulder Arthroplasty,CCOME3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after ACLR Surgery,CCOME4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Extent of Osteoarthritis Observed in Arthroscopic Partial Meniscectomy,CCOME5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Adequate Off-loading of Diabetic Foot Ulcer at each treatment visit,CDR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Vascular Assessment of patients with chronic leg ulcers,CDR10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetic Foot Ulcer (DFU) Healing or Closure,CDR2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Plan of Care Creation for Diabetic Foot Ulcers (DFU) not Achieving 30% Closure at 4 Weeks,CDR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Adequate Compression of Venous Leg Ulcers at each treatment visit,CDR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Venous Leg Ulcer outcome measure: Healing or Closure,CDR6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Plan of Care for Venous Leg Ulcers not Achieving 30% Closure at 4 Weeks,CDR7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate use of hyperbaric oxygen therapy for patients with diabetic foot ulcers,CDR8,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Appropriate use of Cellular and/or Tissue Based Product (CTP) in diabetic foot ulcers (DFUs) or venous leg ulcers (VLUs),CDR9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Post operative hypocalcemia after thyroidectomy surgery,CESQIP1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Related readmission for thyroid or parathyroid related problems,CESQIP2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Pre operative ultrasound exam of patients with thyroid cancer,CESQIP3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Persistent hypercalcemia,CESQIP4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Related readmission for adrenal related problems,CESQIP5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Evaluation and Integration of anti-coagulant medication prior to surgery,CESQIP6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Shoulder Replacement,CODE1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Shoulder Arthroscopy,CODE10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Knee Arthroscopy,CODE11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Hip Arthroscopy,CODE12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for ACL Repair,CODE2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Foot/Ankle Repair,CODE3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Spine Surgery,CODE5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Hip Replacement,CODE6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Knee Replacement,CODE7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Cervical Surgery,CODE8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Hand/Wrist/Elbow Repair,CODE9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"CAHPS Clinician/Group Surveys - (Adult Primary Care, Pediatric Care, and Specialist Care Surveys)",CUHSM3,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
CAHPS Health Plan Survey v 4.0 - Adult questionnaire,CUHSM4,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder,CUHSM6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cardiovascular Health Screening for People With Schizophrenia or Bipolar Disorder Who Are Prescribed Antipsychotic Medications,CUHSM8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoid Head CT for Patients with Uncomplicated Syncope,ECPR39,Registry/QCDR,Process,Y,83.33 - 85.70,85.71 - 88.36,88.37 - 90.47,90.48 - 91.66,91.67 - 93.50,93.51 - 94.99,95.00 - 96.80,>= 96.81,No
Initiation of the Initial Sepsis Bundle,ECPR40,Registry/QCDR,Process,Y,82.05 - 84.95,84.96 - 86.66,86.67 - 89.35,89.36 - 90.90,90.91 - 94.08,94.09 - 95.64,95.65 - 96.54,>= 96.55,No
Rh Status Evaluation and Treatment of Pregnant Women at Risk of Fetal Blood Exposure,ECPR41,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Restrictive Use of Blood Transfusions,ECPR42,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding,ECPR43,Registry/QCDR,Process,Y,15.82 - 10.82,10.81 - 7.82,7.81 - 6.38,6.37 - 5.44,5.43 - 3.44,3.43 - 1.57,1.56 - 0.01,0.00,No
Dental Injury,EPREOP14,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
Ultrasound Guidance for Central Venous Catheter Placement,EPREOP26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Ultrasound Guidance for Peripheral Nerve Block,EPREOP27,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Short-term Pain Management/Maximum Pain Score,EPREOP4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prophylactic Antibiotic Administration,EPREOP9,Registry/QCDR,Process,Y,99.65 - 99.76,99.77 - 99.84,99.85 - 99.91,99.92 - 99.96,99.97 - 99.99,--,--,100.00,Yes
Appropriate management of anticoagulation in the peri-procedural period rate  EGD,GIQIC10,Registry/QCDR,Process,Y,37.84 - 58.45,58.46 - 63.07,63.08 - 68.24,68.25 - 84.84,84.85 - 91.22,91.23 - 99.13,99.14 - 99.99,100.00,No
Appropriate indication for colonoscopy,GIQIC12,Registry/QCDR,Process,Y,83.44 - 87.21,87.22 - 89.96,89.97 - 91.79,91.80 - 93.49,93.50 - 95.18,95.19 - 96.61,96.62 - 98.18,>= 98.19,No
Appropriate follow-up interval of 3 years recommended based on pathology findings from screening colonoscopy in average-risk patients,GIQIC15,Registry/QCDR,Process,Y,61.35 - 71.42,71.43 - 76.92,76.93 - 80.55,80.56 - 83.88,83.89 - 87.40,87.41 - 90.69,90.70 - 93.74,>= 93.75,No
Use of high risk sleep medications in the elderly,HADV1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Atrial fibrillation (afib) prevention and treatment: Patients with afib who are assessed for lifestyle and disease factors that contribute to uncontrolled afib,HADV2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Stroke Venous Thromboembolism (VTE) Prophylaxis,HCPR13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Venous Thromboembolism (VTE) Prophylaxis,HCPR14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Physicians Orders for Life-Sustaining Treatment (POLST) Form,HCPR16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pressure Ulcers  Risk Assessment and Plan of Care,HCPR17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Unintentional Weight Loss  Risk Assessment and Plan of Care,HCPR18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Excess Days Rate and Degree of Excess (Including Physician Response),ICLOPS15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Follow Up Visits Within 7 Days of Discharge (Including Physician Response),ICLOPS17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Corneal Graft Surgery - Post-operative improvement in visual acuity of 20/40 or greater,IRIS1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Exudative Age-Related Macular Degeneration - Loss of Visual Acuity,IRIS10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Nonexudative Age-Related Macular Degeneration - Loss of Visual Acuity,IRIS11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Diabetic Macular Edema - Loss of Visual Acuity,IRIS13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Acute Anterior Uveitis - Post-treatment visual acuity,IRIS16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Acute Anterior Uveitis - Post-treatment Grade 0 anterior chamber cells,IRIS17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Chronic Anterior Uveitis - Post-treatment visual acuity,IRIS18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Chronic Anterior Uveitis - Post-treatment Grade 0 anterior chamber cells,IRIS19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Glaucoma - Intraocular Pressure (IOP)Reduction,IRIS2,Registry/QCDR,Outcome,Y,86.96 - 97.36,97.37 - 98.99,99.00 - 99.99,--,--,--,--,100.00,Yes
Idiopathic Intracranial Hypertension: No worsening or improvement of mean deviation,IRIS20,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Ocular Myasthenia Gravis: Improvement of ocular deviation or absence of diplopia or functional improvement,IRIS21,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Giant Cell Arteritis: Absence of fellow eye involvement after corticosteroid treatment,IRIS22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Refractive Surgery: Postoperative Improvement in Uncorrected Visual Acuity of 20/20 or better,IRIS23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Refractive Surgery: Postoperative correction within + 0.5 Diopter of the Intended Correction,IRIS24,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adenoviral Conjunctivitis: Avoidance of Antibiotics,IRIS25,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Intravitreal Injections: Avoidance of Routine Antibiotic Use,IRIS26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Glaucoma - Visual Field Progression,IRIS3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Glaucoma - Intraocular Pressure Reduction Following Laser Trabeculoplasty,IRIS4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Surgery for Acquired Involutional Ptosis - Patients with an Improvement of Marginal Reflex Distance,IRIS5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Acquired Involutional Entropion - Normalized Lid Position After Surgical Repair,IRIS6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Amblyopia - Interocular Visual Acuity,IRIS7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Surgical Esotropia - Postoperative Alignment,IRIS8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Diabetic Retinopathy - Documentation of the Presence or Absence of Macular Edema and the Level of Severity of Retinopathy,IRIS9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Procedures with statin and antiplatelet agents prescribed at discharge,M2S1,Registry/QCDR,Process,Y,72.50 - 79.54,79.55 - 81.12,81.13 - 81.60,81.61 - 83.77,83.78 - 89.65,89.66 - 90.90,90.91 - 94.73,>= 94.74,No
Survival at least 9 months after elective repair of small thoracic aortic aneurysms,M2S10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Imaging-based maximum aortic diameter assessed at least 9 months following Endovascular AAA Repair procedures,M2S11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Survival at least 9 months after elective repair Endovascular AAA Repair of small abdominal aortic aneurysms,M2S12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Survival at least 9 months after elective Open AAA repair of small abdominal aortic aneurysms,M2S13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Absence of unplanned reoperation after major lower extremity amputation,M2S16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Absence of serious technical complications during peripheral arterial intervention,M2S17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Venous clinical severity score (VCSS) assessment before varicose vein treatment,M2S18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Proper patient selection for perforator vein ablation,M2S19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Amputation-free survival assessed at least 9 months following Infra-Inguinal Bypass for intermittent claudication,M2S2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Infra-inguinal bypass for claudication patency assessed at least 9 months following surgery,M2S3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Amputation-free survival assessed at least 9 months following Supra-Inguinal Bypassfor claudication,M2S4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Amputation-free survival at assessed at least 9 months following Peripheral Vascular Interventionfor intermittent claudication,M2S5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Peripheral Vascular Intervention patency assessed at least 9 months following infrainguinal PVI for claudication,M2S6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Ipsilateral stroke-free survival at assessed at least 9 months following Carotid Artery Stenting for asymptomatic procedures,M2S7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Ipsilateral stroke-free survival assessed at least 9 months following isolated Carotid Endarterectomy for asymptomatic procedures,M2S8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Imaging-based maximum aortic diameter assessed at least 9 months following Thoracic and Complex EVAR procedures,M2S9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Case Delay,MA1,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Corneal Abrasion,MA2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk standardized rate of patients who experienced an unplanned readmission within 30 days,MBSAQIP2,Registry/QCDR,Outcome,Y,4.00 - 3.20,3.19 - 2.50,2.49 - 2.20,2.19 - 1.73,1.72 - 0.01,--,--,0.00,Yes
Risk standardized rate of patients who experienced a reoperation within 30 days,MBSAQIP3,Registry/QCDR,Outcome,Y,0.61 - 0.20,0.19 - 0.01,--,--,--,--,--,0.00,Yes
Risk standardized rate of patients who experienced an anastomotic/staple line leak within 30 days,MBSAQIP4,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
Risk standardized rate of patients who experienced a postoperative surgical site infection (SSI) within 30 days,MBSAQIP6,Registry/QCDR,Outcome,Y,1.54 - 1.20,1.19 - 0.63,0.62 - 0.01,--,--,--,--,0.00,Yes
"Risk standardized rate of patients who experienced postoperative nausea, vomiting or fluid/electrolyte/nutritional depletion within 30 days",MBSAQIP7,Registry/QCDR,Outcome,Y,1.88 - 1.47,1.46 - 1.25,1.24 - 0.75,0.74 - 0.01,--,--,--,0.00,Yes
Risk standardized rate of patients who experienced extended length of stay (> 7 days),MBSAQIP8,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
Hemoglobin A1c Test for Pediatric Patients,MEHC1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Heel Pain Treatment Outcomes for Adults,MEX1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Heel Pain Treatment Outcomes for Pediatric Patients,MEX2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Identification of Flat Foot in Pediatric Patients,MEX3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Plan All Cause Readmissions,MHAN3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
General Health Postoperative Improvement,MICS1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Surgery Specific Postoperative Improvement in Pain Levels,MICS2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Surgery Specific Postoperative Improvement in Function Levels,MICS3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening and patient education for patients meeting guidelines for Colorectal Cancer screening,MIRAMED11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening and patient education for high risk patients meeting guidelines for Lung Cancer Screening with CT,MIRAMED12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening and patient education for high risk patients meeting guidelines for Abdominal Aortic Ultrasound Screening,MIRAMED13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening and patient education for high risk patients meeting guidelines for Breast Cancer screening with MRI,MIRAMED14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening and patient education for high risk patients meeting guidelines for osteoporosis screening,MIRAMED15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Perioperative Pain Plan,MIRAMED16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Dental Injury,MIRAMED3,Registry/QCDR,Intermediate Outcome,Y,99.92 - 99.97,99.98 - 99.99,--,--,--,--,--,100.00,Yes
Perioperative Mortality Rate,MIRAMED4,Registry/QCDR,Outcome,Y,99.98 - 99.98,99.97 - 99.97,99.96 - 99.96,99.95 - 99.95,99.94 - 99.92,99.91 - 99.85,99.84 - 99.75,<= 99.74,No
Adult PACU Pain Management,MIRAMED5,Registry/QCDR,Outcome,Y,99.87 - 99.93,99.94 - 99.97,99.98 - 99.99,--,--,--,--,100.00,Yes
New Corneal Injury Not Diagnosed in the Postanesthesia Care Unit/Recovery Area after Anesthesia Care,MIRAMED7,Registry/QCDR,Outcome,Y,99.98 - 99.99,--,--,--,--,--,--,100.00,Yes
Case Delay Rate,MIRAMED9,Registry/QCDR,Outcome,Y,93.75 - 95.20,95.21 - 97.03,97.04 - 98.03,98.04 - 98.63,98.64 - 99.37,99.38 - 99.80,99.81 - 99.91,>= 99.92,Yes
Optimal Diabetes Care,MNCM1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Optimal Vascular Care,MNCM2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Optimal Asthma Control,MNCM3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Diabetes Hemoglobin A1c Poor Control (>9.0%),MNCM4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Ischemic (IVD): Use of Aspirin or Another Antiplatelet,MNCM5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Objectifying pain and/or functionality to determine manipulative medicine efficacy with correlative treatment adjustment.,MOA1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Treatment of spinal stenosis with manipulative medicine and alternative medicine modalities.,MOA12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Urine Drug Screen Utilization in Pain Management and Substance Use Disorders; no less than quarterly for pain and no less than monthly for substance use disorders.,MOA13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Addressing anxiety in pain patients with SNRI and SSRIs and reducing/eliminating benzodiazepines for chronic anxiety.,MOA14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Weight loss in pain patients with BMI >30 with opiate utilization for weight related pain conditions rather than opiate dose escalation for improved pain control.,MOA15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate use of advanced imaging by ordering provider with glucocorticoid management to spare motor neuron loss when physical findings suggest neuropathic etiology.,MOA2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate controlled substance prescribing (definitive diagnosis(es)) via adherence to Controlled Substance Agreements (CSA) or (OA's) with corrective action taken for pain and/or substance use disorder patients when violations occur.,MOA7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Pre-surgical screening for depression,MSSIC1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percent of patients achieving MCID for pain-related disability (ODI/NDI),MSSIC10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent Satisfied with Result,MSSIC11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted rate of hospital readmission,MSSIC12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted rate of surgical site infection,MSSIC13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted rate of urinary retention,MSSIC14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Return to OR Rate,MSSIC15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Assessment of back or neck pain,MSSIC2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Assessment of leg or arm pain,MSSIC3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Assessment of pain-related disability (ODI/NDI),MSSIC4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Follow-up (90 day) assessment of myelopathy (cervical only),MSSIC5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percent same-day ambulation,MSSIC6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of use of Pre-op skin preparation/wash,MSSIC7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percent of patients achieving MCID for back or neck pain,MSSIC8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients achieving MCID for leg or arm pain,MSSIC9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Biopsy Antibiotic Compliance,MUSIC1,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Prostate Cancer: Confirmation Testing in low risk AS eligible patients,MUSIC10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Follow-Up Testing for patients on active surveillance for at least 30 months,MUSIC11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Biopsy: Unplanned Hospital Admission within 30 Days of TRUS Biopsy,MUSIC2,Registry/QCDR,Outcome,Y,0.86 - 0.01,--,--,--,--,--,--,0.00,Yes
Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients,MUSIC3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Active Surveillance/Watchful Waiting for Low Risk Prostate Cancer Patients,MUSIC4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Radical Prostatectomy Cases LOS,MUSIC5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Unplanned Hospital Readmission After Radical Prostatectomy,MUSIC6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Biopsy: Repeat Biopsy for Patients with Atypical Small Acinar Proliferation (ASAP),MUSIC9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Telephone Contact, Virtual, or In-person Visit Within 48 Hours of Hospital Discharge of Home-Based Primary Care and Palliative Care Patients",NHBPC10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Medication Reconciliation Within 2 Weeks of Hospital Discharge of Home-Based Primary Care and Palliative Care Patients,NHBPC11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Interdisciplinary Team Assessment for Home-Based Primary care and Palliative Care Patients,NHBPC13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cognitive Assessment for Home-Based Primary Care and Palliative Care Patients,NHBPC14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
A Functional Assessment (Basic and Instrumental Activities of Daily Living [ADL]) for Home-Based Primary Care and Palliative Care Patients (Multiperformance Measure),NHBPC15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Reported Outcome for Home-Based Primary Care and Palliative Care Practices,NHBPC16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Alcohol Problem Use Assessment for Home-Based Primary Care and Palliative Care Patients,NHBPC2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Depression Symptom Assessment for Home-Based Primary Care and Palliative Care Patients,NHBPC3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pain Screen for Home-Based Primary Care and Palliative Care Patients,NHBPC4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Depression Treatment Plan for Home-Based Primary Care and Palliative Care Patients Who Screen Positive for Depression,NHBPC5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Screen for Risk of Future Fall for Home-Based Primary Care and Palliative Care Patients,NHBPC6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Delirium Assessment in Home-Based Primary Care and Palliative Care Patients: Medication List Reviewed & Offending Medications Discontinued (Multiperformance-Rate Measure),NHBPC7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Referral to Hospice for Appropriate Home-Based Primary Care and Palliative Care Patients,NHBPC9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation,NHCR4,Registry/QCDR,Outcome,Y,12.90 - 20.74,20.75 - 27.58,27.59 - 36.75,36.76 - 42.30,42.31 - 52.37,52.38 - 67.85,67.86 - 80.59,>= 80.60,No
Colonoscopy: Repeat colonoscopy recommended due to piecemeal resection,NHCR5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
AVOIDING EXCESSIVE USE OF EPIDURAL INJECTIONS IN MANAGING CHRONIC PAIN ORIGINATING IN THE LUMBOSACRAL SPINE,NIPM1,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
RATE OF CAUDAL AND INTERLAMINAR EPIDURAL INJECTIONS WITHOUT DURAL PUNCTURE,NIPM2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
AVOIDING EXCESSIVE USE OF THERAPEUTIC FACET JOINT INTERVENTIONS IN MANAGING CHRONIC LUMBAR SPINAL PAIN,NIPM3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
APPROPRIATE PATIENT SELECTION FOR DIAGNOSTIC FACET JOINT PROCEDURES,NIPM4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
APPROPRIATE PATIENT SELECTION FOR TRIAL SPINAL CORD STIMULATION,NIPM5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"APPROPRIATE PATIENT SELECTION FOR USE OF EPIDURAL INJECTIONS IN MANAGING PAIN ORIGINATING IN THE SACRAL, LUMBAR, THORACIC OR CERVICAL SPINE",NIPM6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SHARED DECISION MAKING REGARDING ANTICOAGULANT AND ANTITHROMBOTIC USE IN THE SETTING OF CAUDAL OR INTERLAMINAR EPIDURAL INJECTIONS,NIPM7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"AVOIDING EXCESSIVE USE OF EPIDURAL INJECTIONS IN MANAGING CHRONIC PAIN ORIGINATING IN THE CERVICAL AND THORACIC SPINE

(Measure 18)",NIPM8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"AVOIDING EXCESSIVE USE OF THERAPEUTIC FACET JOINT INTERVENTIONS IN MANAGING CHRONIC CERVICAL AND THORACIC SPINAL PAIN

(Measure 19)",NIPM9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Pulmonary Embolism,NJIISMD1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Ruptured Ectopic Pregnancy,NJIISMD10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: New Deep Venous Thrombosis (DVT),NJIISMD11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Ectopic Pregnancy,NJIISMD12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Test Protocol,NJIISMD13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Critical Result Protocol,NJIISMD14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Urgent Result Protocol,NJIISMD15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Unexpected Result Protocol,NJIISMD16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Result Requiring Follow Up Protocol,NJIISMD17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Finding: Cord Compression,NJIISMD19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: ICH,NJIISMD2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Finding: CTA of GI bleed,NJIISMD20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Finding: Positive bleeding scan,NJIISMD21,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Critical Finding: Acute Ocular injury,NJIISMD22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Aortic Dissection,NJIISMD3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical test: OR Foreign Body,NJIISMD4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Critical test: Stroke,NJIISMD5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Critical test: Intracranial Hemorrhage,NJIISMD6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Critical test: Aortic Dissection,NJIISMD7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Critical Result: Occlusive Intracranial Stroke,NJIISMD8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Critical Result: Placental abruption,NJIISMD9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Substance Use Screening,NNEPTN1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Transforming Clinical Practice Initiative Common Measure Name: Substance Use Screening and Intervention Composite,NNEPTN2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Transforming Clinical Practice Initiative Common Measure Name: TCPI 01: Documentation of a Comprehensive Health and Life Plan Developed Collaboratively by the Patient and the Health Professional Team,NNEPTN3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Transforming Clinical Practice Initiative Common Measure Name: TCPI 02: Referral of At-Risk Patients to Community Based Prevention and Support Resources,NNEPTN4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older",NOF13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hip Fracture Mortality Rate (IQI 19),NOF6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Osteoporosis: percentage of patients, any age, with a diagnosis of osteoporosis who are either receiving both calcium & vitamin D intake, & exercise at least once within 12 months.",NOF7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Unplanned Readmission Following Spine Procedure within the 30-day Postoperative Period,NPA11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Selection of Prophylactic Antibiotic Prior to Spine Procedure,NPA12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Medicine Reconciliation Following Spine Related Procedure,NPA14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Risk Assessment for Elective Spine Procedure,NPA15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Depression and Anxiety Assessment Prior to Spine-Related Therapies,NPA16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Narcotic Pain Medicine Management Following Elective Spine Procedure,NPA17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Smoking Assessment and Cessation Coincident with Spine-Related Therapies,NPA18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Body Mass Assessment and Follow-up Coincident with Spine-Related Therapies,NPA19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Unhealthy Alcohol Use Assessment Coincident with Spine Care,NPA20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Spine/Extremity Pain Assessment,NPA22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Outcome Assessment for Spine Intervention,NPA3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Quality-of-Life Assessment for Spine Intervention,NPA4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Satisfaction with Spine Care,NPA5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Spine-Related Procedure Site Infection,NPA6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Referral for Post-Acute Care Rehabilitation Following Spine Procedure,NPA9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Spine/Extremity Pain Assessment,NPAGSC10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Outcome Assessment for Spine Intervention,NPAGSC3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Quality-of-Life Assessment for Spine Intervention,NPAGSC4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Satisfaction with Spine Care,NPAGSC5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Depression and Anxiety Assessment Prior to Spine-Related Therapies,NPAGSC6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Complication Following Percutaneous Spine-Related Procedure,NPAGSC8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Admission to Hospital Following Percutaneous Spine Procedure within the 30-Day Post-procedure Period,NPAGSC9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Satisfaction: CG-CAHPS Composite Tracking v,OBERD12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Post-Stroke Outcome and Follow-up,OBERD22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Health Related Quality of Life: Patient Defined Outcomes,OBERD23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Inflamatory Bowel Disease: Follow-up and Outcomes,OBERD24,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Satisfaction: Tracking Satisfaction Improvement with CG-CAHPS,OBERD25,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Optimal vascular care,OEIS1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Emergent transfer from an outpatient, ambulatory surgical center, or office setting",OEIS2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Antiplatelet Therapy,OEIS3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Lipid-Lowering Medications for Patients with PAD,OEIS4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate non-invasive arterial testing for patients with critical limb ischemia who are undergoing a LE peripheral vascular intervention,OEIS5,Registry/QCDR,Structure,N,--,--,--,--,--,--,--,--,--
Appropriate non-invasive arterial testing for patients with intermittent claudication who are undergoing a LE peripheral vascular intervention,OEIS6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Assessment and Intervention for Psychosocial Distress in Adults Receiving Cancer Treatment,ONSQIR15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Recommendation for Exercise to Adult Cancer Survivors,ONSQIR16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Assessment and Intervention for Sleep-Wake Disturbance During Cancer Treatment,ONSQIR17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Goal Setting and Attainment for Cancer Survivors,ONSQIR18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Post-Treatment Education,ONSQIR19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Fatigue Improvement,ONSQIR20,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Education on Neutropenia Precautions,ONSQIR6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Surgical Site Infection (SSI),PINC51,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Postoperative Sepsis Rate,PINC53,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Iatrogenic Pneumothorax,PINC54,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Annual Monitoring for Patients on Persistent Medications (MPM),PP1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Follow-Up After Hospitalization for Schizophrenia (7- and 30-day),PP2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Chronic Kidney Disease (CKD): eGFR Monitoring,PPRNET13,Registry/QCDR,Process,Y,60.78 - 64.85,64.86 - 70.58,70.59 - 73.42,73.43 - 76.04,76.05 - 83.11,83.12 - 85.70,85.71 - 89.05,>= 89.06,No
Chronic Kidney Disease (CKD): Hemoglobin Monitoring,PPRNET14,Registry/QCDR,Process,Y,72.22 - 75.89,75.90 - 82.85,82.86 - 87.64,87.65 - 90.23,90.24 - 91.42,91.43 - 94.11,94.12 - 94.58,>= 94.59,No
Herpes Zoster (Shingles) Vaccination,PPRNET20,Registry/QCDR,Process,Y,22.59 - 37.47,37.48 - 46.73,46.74 - 50.72,50.73 - 53.31,53.32 - 58.61,58.62 - 64.73,64.74 - 71.51,>= 71.52,No
Appropriate Treatment for Adults with Upper Respiratory Infection,PPRNET24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Use of Benzodiazepines in the Elderly,PPRNET27,Registry/QCDR,Process,Y,88.29 - 90.29,90.30 - 91.26,91.27 - 91.71,91.72 - 95.13,95.14 - 97.48,97.49 - 99.08,99.09 - 99.99,100.00,No
NSAID or Cox 2 Inhibitor Use in Patients with Heart Failure (HF) or Chronic Kidney Disease (CKD),PPRNET28,Registry/QCDR,Process,Y,81.30 - 82.04,82.05 - 83.93,83.94 - 85.10,85.11 - 85.94,85.95 - 86.76,86.77 - 88.30,88.31 - 93.07,>= 93.08,No
Monitoring Serum Creatinine,PPRNET29,Registry/QCDR,Process,Y,73.35 - 78.88,78.89 - 84.40,84.41 - 86.13,86.14 - 88.09,88.10 - 90.88,90.89 - 93.27,93.28 - 96.16,>= 96.17,No
Treatment of Hypokalemia,PPRNET30,Registry/QCDR,Outcome,Y,95.77 - 96.61,96.62 - 97.33,97.34 - 97.76,97.77 - 98.06,98.07 - 98.44,98.45 - 98.89,98.90 - 99.37,>= 99.38,Yes
Screening for Type 2 Diabetes,PPRNET31,Registry/QCDR,Process,Y,82.72 - 83.35,83.36 - 84.70,84.71 - 85.64,85.65 - 90.70,90.71 - 92.15,92.16 - 93.41,93.42 - 95.21,>= 95.22,No
Screening for albuminuria in patients at risk for CKD (DM and/or HTN),PPRNET32,Registry/QCDR,Process,Y,18.26 - 26.78,26.79 - 47.26,47.27 - 54.80,54.81 - 61.65,61.66 - 66.11,66.12 - 67.83,67.84 - 74.18,>= 74.19,No
Avoiding Use of CNS Depressants in Patients on Long-Term Opioids,PPRNET33,Registry/QCDR,Process,Y,51.21 - 54.54,54.55 - 55.34,55.35 - 57.57,57.58 - 62.62,62.63 - 68.92,68.93 - 74.08,74.09 - 81.62,>= 81.63,No
Antiplatelet Medication for High Risk Patients,PPRNET8,Registry/QCDR,Process,Y,26.58 - 30.48,30.49 - 40.54,40.55 - 46.83,46.84 - 50.37,50.38 - 57.13,57.14 - 67.03,67.04 - 68.60,>= 68.61,No
Opioid Therapy Follow-up Evaluation (Q408),Q408,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Evaluation or Interview for Risk of Opioid Misuse (Q414),Q414,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,Q415,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,Q416,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) to III ER/PR negative breast cancer,QOPI11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
GCSF administered to patients who received chemotherapy for metastatic cancer (Lower score-better),QOPI15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Chemotherapy administered to patients with metastatic solid tumors and performance status of 3,4, or undocumented (lower score-better)",QOPI5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Central Line Ultrasound Guidance,QUANTUM31,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Gastric Aspiration,QUANTUM37,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Case Cancellation on Day of Surgery,QUANTUM41,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Hospital Admission After An Intended Outpatient Procedure,QUANTUM42,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned ICU Admission,QUANTUM51,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CKD 3-5 Patients Seen at the Recommended Frequency Levels,RCOIR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Upper Extremity Edema Improvement,RCOIR10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patients with a Visit to a Nephrologists Prior to 6 Months of Dialysis Onset,RCOIR2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CKD 3-5 Patients with a Urine ACR or Urine PCR Lab Test,RCOIR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CKD 4-5 Patients with Transplant Referral,RCOIR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
End Stage Renal Disease (ESRD) Initiation of Home Dialysis or Self-Care,RCOIR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
End Stage Renal Disease (ESRD) Missed Dialysis Treatments,RCOIR6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Improved Access Site Bleeding,RCOIR7,Registry/QCDR,Outcome,Y,33.33 - 39.42,39.43 - 42.41,42.42 - 57.60,57.61 - 63.63,63.64 - 66.66,66.67 - 69.22,69.23 - 74.99,>= 75.00,No
Post Procedure Bleeding,RCOIR8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Post Procedure Infection,RCOIR9,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100.00,Yes
Diabetic patients with significant change in HgbA1C level or overall change in HgbA1C,RHI1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Hypertensive patients with significant change in systolic blood pressure or overall change in systolic pressure,RHI2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patients who have a change in tobacco use status (Improvement),RHI3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patients with Change in BMI,RHI4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Low back pain patients who undergo an operative procedure on the spine within 12 weeks after a referral from a primary care physician,RHI5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Breast Mass Follow Up: Percent of patients with a breast mass who do not have follow-up physician contact,RHI6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Uncontrolled chronic disease patients without a follow-up office visit,RHI7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Angiotensin Converting Enzyme (ACE) Inhibitor or AngiotensinReceptor Blocker (ARB) Therapy,RPAQIR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hospitalization Rate Following Procedures Performed under Procedure Sedation Analgesia,RPAQIR11,Registry/QCDR,Outcome,Y,0.60 - 0.29,0.28 - 0.15,0.14 - 0.01,--,--,--,--,0.00,Yes
Arterial Complication Rate Following Arteriovenous Access Intervention,RPAQIR12,Registry/QCDR,Outcome,Y,0.99 - 0.74,0.73 - 0.52,0.51 - 0.39,0.38 - 0.01,--,--,--,0.00,Yes
Rate of Timely Documentation Transmission to Dialysis Unit/Referring Physician,RPAQIR13,Registry/QCDR,Process,Y,92.89 - 94.06,94.07 - 94.54,94.55 - 95.79,95.80 - 96.96,96.97 - 97.88,97.89 - 99.04,99.05 - 99.76,>= 99.77,Yes
Arteriovenious Graft Thrombectomy Success Rate,RPAQIR14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Arteriovenous Fistulae Thrombectomy Success Rate,RPAQIR15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Peritoneal Dialysis Catheter Success Rate,RPAQIR16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Peritoneal Dialysis Catheter Exit Site Infection Rate,RPAQIR17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Advance Directives Completed,RPAQIR18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Adequacy of Volume Management,RPAQIR2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Arteriovenous Fistula Rate,RPAQIR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Transplant Referral,RPAQIR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Advance Care Planning (Pediatric Kidney Disease),RPAQIR9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Improvement in Quality of Life from Partial Foot, Prosthetics",SCG05,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Evaluation of High Risk Pain Medications for Morphine Milligram Equivalents (MME),SCG1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Outcome Assessment for Patients Prescribed Ankle Orthosis for Ambulation and Functional Improvement,SCG2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Outcome Assessment for Patients Prescribed Foot Orthosis for Ambulation and Functional Improvement,SCG3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prevention of Antibiotic or Natural Herbal Supplement Impairment of Anesthesia,SCG4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Education of patients with inflammatory diseases regarding increased cardiovascular risk and the need for PCP evaluation,SDPAD1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HCV testing in Lichen Planus,SDPAD2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoiding antibiotic use in ruptured epidermal inclusion cyst,SDPAD3,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Appropriate Testing and Treatment of Nail tinea infection,SDPAD4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia,SMX1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications,SMX2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Use of Multiple Concurrent Antipsychotics in Children and Adolescents,SMX3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Metabolic Monitoring for Children and Adolescents on Antipsychotics,SMX4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Repeated X-ray Imaging,SPINEIQ3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prolonged Length of Stay Following Coronary Artery Bypass Grafting,STS1,Registry/QCDR,Outcome,Y,8.20 - 6.91,6.90 - 5.89,5.88 - 4.23,4.22 - 3.58,3.57 - 2.84,2.83 - 2.10,2.09 - 0.97,<= 0.96,No
Prolonged Length of Stay for Coronary Artery Bypass Grafting (CABG) + Valve Replacement,STS3,Registry/QCDR,Outcome,Y,21.21 - 15.70,15.69 - 9.10,9.09 - 8.01,8.00 - 6.91,6.90 - 5.01,5.00 - 4.36,4.35 - 2.71,<= 2.70,Yes
Prolonged Length of Stay following Valve Surgery,STS5,Registry/QCDR,Outcome,Y,8.00 - 6.26,6.25 - 5.27,5.26 - 4.31,4.30 - 3.58,3.57 - 2.71,2.70 - 1.60,1.59 - 0.01,0.00,No
Patient Centered Surgical Risk Assessment and Communication for Cardiac Surgery,STS7,Registry/QCDR,Patient Engagement Experience,Y,2.56 - 4.94,4.95 - 9.16,9.17 - 26.78,26.79 - 59.56,59.57 - 78.07,78.08 - 91.59,91.60 - 97.72,>= 97.73,No
"Patient Vital Sign Assessment and Blood Glucose Check Prior to Hyperbaric Oxygen
Therapy (HBOT) Treatment",USWR13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Healing or Closure of Wagner Grade 3, 4 or 5 Diabetic Foot Ulcers (DFUs) Treated with HBOT",USWR15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Major Amputation in Wagner Grade 3, 4 or 5 Diabetic Foot Ulcers (DFUs) Treated with HBOT",USWR16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Nutritional Screening and Intervention Plan in Patients with Chronic Wounds and Ulcers,USWR20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Wound Outcome,USWR21,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Reported Nutritional Assessment in Patients with Wounds and Ulcers,USWR22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Diabetes Care All or None Outcome Measure: Optimal Control,WCHQ10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Ischemic Vascular Disease Care Blood Pressure Control,WCHQ13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Screening For Osteoporosis,WCHQ15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Controlling High Blood Pressure: eGFR Test Annually,WCHQ32,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes Care All or None Process Measure: Optimal Testing,WCHQ9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Nutritional Screening and Intervention Plan in Patients with Chronic Wounds and Ulcers,WCQIC16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,cmsWebInterface,Intermediate Outcome,Y,100 - 70,70 - 60,60 - 50,50 - 40,40 - 30,30 - 20,20 - 10,<= 10,No
Preventive Care and Screening: Influenza Immunization,110,cmsWebInterface,Process,Y,0 - 30,30 - 40,40 - 50,50 - 60,60 - 70,70 - 80,80 - 90,>= 90,No
Breast Cancer Screening,112,cmsWebInterface,Process,Y,0 - 30,30 - 40,40 - 50,50 - 60,60 - 70,70 - 80,80 - 90,>= 90,No
Colorectal Cancer Screening,113,cmsWebInterface,Process,Y,0 - 30,30 - 40,40 - 50,50 - 60,60 - 70,70 - 80,80 - 90,>= 90,No
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,cmsWebInterface,Process,Y,0 - 30,30 - 40,40 - 50,50 - 60,60 - 70,70 - 80,80 - 90,>= 90,No
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,cmsWebInterface,Process,Y,0 - 55.22,55.22 - 61.76,61.76 - 68.18,68.18 - 73.85,73.85 - 79.55,79.55 - 85.67,85.67 - 92.31,>= 92.31,No
Controlling High Blood Pressure,236,cmsWebInterface,Intermediate Outcome,Y,0 - 30,30 - 40,40 - 50,50 - 60,60 - 70,70 - 80,80 - 90,>= 90,No
Falls: Screening for Future Fall Risk,318,cmsWebInterface,Process,Y,0 - 43.42,43.42 - 50.42,50.42 - 58.45,58.45 - 66,66 - 73.39,73.39 - 81.79,81.79 - 90.73,>= 90.73,No